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Abstract 
 
Purpose: To derive dose-response parameters for the radiation therapy side-effect 
xerostomia in head and neck tumour patients treated at IPOCFG. 
 
Methods and Materials: A total of 302 patients with head and neck tumours treated 
with Intensity Modulated Radiation Therapy (IMRT) were included in this study. 
Acute and late xerostomia evaluated according to the guidelines established by the 
Radiation Therapy Oncology Group and the European Organization for Research and 
Treatment of Cancer (RTOG/EORTC) were studied. DRC were derived for the 
Relative Seriality model at the follow-up times: 7 weeks, 3, 7, 12, 18 and 24 months. 
The incidence of complications was determined by dividing the patients into: Grade 0 
(G0, complication-free) vs. Grade 2 (G2, moderate severity) and G0 vs. G1+G2 
(mild+moderate). The dose that irradiated the contralateral parotid, the ipsilateral 
parotid, both parotids and all salivary glands was used to establish dose-response 
relations. Goodness of the fit was evaluated using the ROC curve, Pearson’s X2-test 
and Worst-fit methods. 
 
Results: The values of D50, γ and s for xerostomia G2 at the follow-up times of 12, 18 
and 24 months considering the dose that irradiated the contralateral parotid were 38.6, 
0.707, 1x10-4; 51.7, 0.444, 1x10-4; and 48.3, 0.685, 1x10-4, respectively. Similarly, for 
the sum of the parotids these were 39.2, 0.730, 1x10-4; 54.2, 0.468, 1x10-4; and 51.7, 
0.633, 1x10-4, respectively. Statistical analysis showed that the derived Relative 
Seriality model quantifying xerostomia G2 based on the dose that irradiated the 
contralateral parotids and the sum of the parotids has a reasonable-good quality (range 
0.6-0.7) while the model derived quantifying G1+G2 xerostomia only reached 
reasonable quality (~0.6). 
 
Conclusions: Using the derived parameters for the Relative Seriality model, a better 
prediction of the probability of xerostomia G2 may be made compared to xerostomia 
G1+G2. The best radiobiological parameters were found using the dose irradiating the 
contralateral parotids and sum of the parotids, for the follow-up times of 12, 18 and 
 vi 
24 months. To minimize the probability of xerostomia the dose in the parotids should 
be below 28Gy. 
 
Xerostomia, Salivary glands, Dose-response curves, Relative Seriality model, 
Head and neck tumours. 
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Resumo 
 
Objetivo: Derivação de parâmetros dose-resposta para efeitos secundário da 
radioterapia, xerostomia, em doentes com tumores de cabeça e pescoço tratados no 
IPOCFG. 
 
Métodos e Materiais:  Um total de 302 pacientes com tumores de cabeça e pescoço, 
tratados com Radioterapia de Intensidade Modulada (IMRT), foram incluídos neste 
estudo. O efeito secundário estudado foi xerostomia aguda e tardia, avaliadas segundo 
as recomendações do Radiation Therapy Oncology Group e da European 
Organization for Research and Treatment of Cancer (RTOG/EORTC). Foram 
derivadas curvas de dose-resposta para o modelo Relative Seriality para os períodos 
de follow-up: 7 semanas, 3, 7, 12, 18 e 24 meses. A incidência de complicações foi 
determinada através da divisão dos doentes em: Grau 0 (G0, sem complicações) vs. 
Grau 2 (G2, severidade moderada) e G0 vs. G1+G2 (suave+moderada). Para 
estabelecer as relações de dose-efeito, foi considerada a dose fornecida na parótida 
contra-lateral, parótida ipsilateral, soma das parótidas e glândulas salivares. A 
qualidade do ajuste foi avaliada através dos métodos: curvas ROC, Pearson’s X2-test e 
Worst-fit. 
 
Resultados: Os valores de D50, γ e s para a xerostomia G2 nos períodos de follow-up 
de 12,18 e 24 meses considerando a dose fornecida na parótida contra-lateral foram 
38.6, 0.707, 1x10-4; 51.7, 0.444, 1x10-4; e 48.3, 0.685, 1x10-4, respetivamente. Para a 
soma das parótidas estes foram 39.2, 0.730, 1x10-4; 54.2, 0.468, 1x10-4; e 51.7, 0.633, 
1x10-4, respetivamente. A análise estatística do modelo demonstrou que o modelo 
Relative Seriality para xerostomia G2 considerando a dose fornecida nas parótidas 
contra-laterais e soma das parótidas tem uma qualidade razoável-boa (intervalo de 0.6 
a 0.7) enquanto que o modelo derivado para quantificar a xerostomia G1+G2 só 
atingiu uma qualidade razoável (aproximadamente 0.6). 
 
Conclusões: Usando os parâmetros derivados para o modelo Reltive Seriality, pode 
ser feita uma melhor previsão da probabilidade de xerostomia G2, do que para 
xerostomia G1+G2. Os melhores parâmetros rádio-biológicos foram obtidos através 
 viii 
da utilização da dose que irradiou as parótidas contra-laterais e soma das parótidas 
para os períodos de follow-up de 12, 18 e 24 meses. De forma a minimizar a 
probabilidade de xerostomia, a dose administrada às parótidas deve ser inferior a 
28Gy. 
 
Xerostomia, Glândulas salivares, Curvas dose-resposta, Modelo Relative 
Seriality, Tumores de cabeça e pescoço. 
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CHAPTER 1: Introduction 
1.1 Theoretical Framework 
In 1895 a big discovery marked the health sector when Roentgen discovered the x-
rays. X-rays started being used to treat skin lesions in a very short time. However, the 
physical effects of the radiation beams in tissues were not yet known. The outcome of 
the first treated patients wasn’t as good as expected due to inability to control the 
cancer and the large morbidity. In 1897 Henri Becquerel discovered the radioactivity, 
which was further studied by Marie and Pierre Curie in 1898, giving rise to the 
discovery of two radioactive elements: radium and polonium. Suppositions that 
radium rays could be used to treat diseases lead to studies about the biological effects 
of the radiation beams in tissues and to improvements in the delivery of the radiation. 
In 1928 R. Wideroe showed that electrons can be accelerated in a tube through the 
application of a certain radio frequency voltage in separated sections of the tube so 
that when arriving to a gap they would be accelerated with the double of the energy. 
This idea was applied to the construction of electron linear accelerators, which 
became clinically available in 1950. Yet, with x-rays beams high doses in normal 
tissues and tumours were still being delivered. Subsequently, in 1965 Takahashi S. 
created the multi-leaf collimator. This is composed by a set of independent leaves that 
move into pre-defined segments controlling the shape of the beam [1-4]. 
The goal of radiation therapy consists on the control/reduction of the tumour and 
minimizing the damages in normal tissues. To achieve that goal, a plan is made for 
the patient to maximize the irradiation of the tumour while protecting the organs at 
risk that surround the tumour. Depending on the radiosensitivity of the patient and the 
dose delivered, the irradiation of healthy tissues may lead to the development of side-
effects. For patients with head and neck tumours important organs at risk are the 
parotid glands and oral cavity, whose irradiation above the tolerance may cause 
complications like, xerostomia, mucositis and earing loss. 
 
 
CHAPTER 1: Introduction 
 2 
1.2 Aim 
The aim of this master thesis consisted in the derivation of the dose-response 
parameters of the Relative Seriality model for the radiation therapy side-effect: 
xerostomia. The clinical data from head and neck tumour cases treated with radiation 
therapy at IPOCFG since 2007 were used in this study. The goodness of the fit of the 
derived models was evaluated through a statistical analysis using the methods: 
Receiving Operator Characteristic curve, Pearson’s X2-test and Worst-fit. A 
comparison with the parameters published in literature was also made. 
 
 
1.3 Organization of the Dissertation 
This thesis was divided into six chapters: 
• CHAPTER 1: Introduction – this chapter presented a theoretical 
framework of this thesis and its main goal; 
• CHAPTER 2: H&N Radiation Therapy – in this chapter the basics of 
the radiation therapy for head and neck tumours are presented. The 
concept of Image-Guided Radiation Therapy is discussed and some 
radiobiological dose-response models are introduced; 
• CHAPTER 3: Materials & Methods –this chapter is divided into two 
parts. The first part presents the criteria for patient selection and treatment 
details. The second part describes the statistical methods used to evaluate 
the goodness of the fit of the Relative Seriality model; 
• CHAPTER 4: Results – here the results obtained are presented. This 
chapter is composed by three sections: G0 vs. G2, G0 vs. G1+G2 and the 
comparison between mean dose values and Biological Effective Uniform 
Dose values; 
• CHAPTER 5: Discussion – in this chapter the results are discussed. 
Dose-response curves derived for different structures and time periods are 
compared; 
• CHAPTER 6: Conclusions – summarizes the conclusions achieved 
through this study and future studies are proposed. 
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CHAPTER 2: H&N Radiation Therapy 
2.1 Target Volumes & Organs at Risk 
There are several imaging means for the diagnosis of oncological problems as, e.g. 
the Magnetic Resonance Imaging (MRI), the Positron Emission Tomography (PET) 
and the Computed Tomography (CT) scan, which allow diagnosis. After a patient has 
been diagnosed, he will be forwarded to an oncological institution where a multi-
disciplinary board will decide the proper care (Figure 1). Generally in 50% of the 
patients radiation therapy is recommended. 
 
 
Figure 1 – Workflow of radiation therapy [5]. 
Most of radiation therapy treatments are delivered in multiple fractions. In head 
and neck tumour cases an immobilization mask is made to guarantee that the patient 
will reproduce the position of the planning CT through all the fractions of the 
radiation therapy treatment (Figure 2).  
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Figure 2 – Immobilization mask used to treat head and neck tumour cases at IPOCFG [courtesy of 
IPOCFG]. 
In the planning CT scan the physician will outline the target volumes and the 
organs at risk. For the delineation of the target volume and organs at risk a strict set of 
guidelines must be followed (Figure 3) [5,6]: 
• Gross Tumour Volume (GTV) – perceptible extent and location of the 
primary tumour. For those patients that had previously done a complete 
surgical resection (postoperative), there is no GTV; 
• Clinical Target Volume (CTV) – volume that contains the GTV and a margin 
that takes into account microscopic disease; 
• Planning Target Volume (PTV) – volume containing the GTV, CTV and a 
margin around the CTV that accounts for variations and inaccuracies due to 
organ motion and setup errors in order to ensure that the CTV receives the 
prescribed dose; 
• Organs at Risk (OAR) – normal tissues that constrain the dose prescribed to 
the tumour. These organs may have different classifications depending on 
their functional organization. These may be (Figure 4): 
o Serial – if a functional sub-unit of the chain receives a radiation dose 
above the tolerance organ functionality is lost (e.g. spinal cord); 
o Parallel – the functional sub-units of the organ are independent thus, 
if only one small volume of the organ is damaged it won’t affect 
organ function (e.g. parotid glands); 
o Mixed – tissues that have functional sub-units with both behaviours 
(serial and parallel). 
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Due to internal organ motion and setup uncertainties a margin around the organs at 
risk may be used, the Planning Risk Volume (PRV) [7]. 
 
 
Figure 3 – Target volumes (GTV, CTV and PTV), treated volume and volume irradiated [8]. 
 
 
Figure 4 – Tissue organization structures: (a) serial, (b) parallel, (c) serial-parallel and (d) mixed [7]. 
For head and neck tumours the most important organs at risk are the spinal cord, 
brainstem, parotid glands, oral cavity, mandible, thyroid, optical nerves, oesophagus, 
pharynx, larynx, brachial plexus, etc. (Figure 5). Irradiation of these structures above 
the tolerance dose may cause complications such as patient paralysis, xerostomia, 
mucositis, osteoradionecrois, hypothryrodism, blindness, etc. 
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Figure 5 – Two slices of a CT scan (axial on the left and coronal on the right) from a patient treated at 
IPOCFG. In this patient the organs at risk delineated were: mandible, spinal cord and margin – PRV-spinal 
cord –, thyroid, parotid glands and the target volumes to be treated (PTV-T: primary tumour; CTV-N1 and 
N2: adenopathies; PTV-N1 and N2: regions with a small probability of disease) [courtesy of IPOCFG]. 
 
 
2.2 Salivary Glands 
The salivary glands can be divided in two groups: the minor salivary glands which 
are hundreds spread all over the oral cavity (lips, cheeks, palate, floor of the mouth 
and part of the tongue) and oropharynx; and the major salivary glands, which include 
both parotids, submandibular and sublingual glands (Figure 6). The parotid glands are 
located in the preauricular region and posterior area of the mandible, and the 
submandibular glands are positioned beneath the floor of mouth along the interior of 
the mandible. The sublingual glands are anterior at the submandibular glands [9,10]. 
 
 
Figure 6 - Major salivary glands [10]. 
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Each salivary gland secretes fluids that when mixed originate the saliva. The 
saliva has several roles as, for example, lubrication and protections of the oral tissues, 
facilitating speech and aiding the digestion of food. These are all functions important 
to maintain a good quality of life. 
For patients with head and neck cancers one of the most important acute and late 
side effects of radiation therapy is usually related to a dysfunction in the salivary 
glands called xerostomia. This dysfunction consists on a reduction on the saliva 
production leading to oral dryness, thick/sticky saliva and difficulties in speech, 
chewing or swallowing [11,12]. 
Radiation therapy side effects may be considered early or late if those occurred 6 
months before or after the start of radiation therapy treatment, respectively. The side 
effects are usually graded according to their severity where for example G0 
corresponds to complication-free and G4 corresponds to severe/irreversible 
complications (Table 1). 
 
Table 1 – Acute and late radiation endpoints for xerostomia according to RTOG/EORTC guidelines [13]. 
Severity Endpoints Acute Late 
G0 • None • None 
G1 • Slight disgeusia 
• Mild xerostomia 
• Slight xerostomia 
• Good response to stimulation 
G2 • Severe disgeusia 
• Moderate xerostomia 
• Bad response to stimulation 
Moderate xerostomia 
G3 - • Complete xerostomia 
• No response to stimulation 
G4 • Gland necrosis • Fibrosis 
 
 
2.3 Treatment Planning 
The third step in the workflow of radiation therapy, after structure delineation, is 
the treatment planning. This may be made by the physicist or dosimetrist in the 
Treatment Planning System (Figure 1). 
Today the most common form of radiation therapy is 3D Conformal Radiation 
Therapy, which is generally based on forward planning. In this case, during plan 
optimization the beams number, directions, energy and shapes are manually defined 
by the planner until a good dose distribution is obtained. This is a trial and error 
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process where all these variables are continuously changed to improve plan quality. 
When an adequate dose distribution is obtained the physician will then evaluate the 
plan and approve the treatment. The evaluation of plan quality is based on dose 
statistics, dose-volume histograms (DVH) and 3D dose distributions. Dose-volume 
histograms quantify the percentage of volume that receives a certain dose value, both 
for organs at risk and target volumes (Figure 7) [5]. 
 
 
Figure 7 – Example of dose-volume histograms for target volumes (PTV-T, PTV-N1 and PTV-N2) and 
organs at risk (spinal cord, contralateral parotid, ipsilateral parotid and oral cavity). 
 
 
2.4 RT Techniques 
3D Conformal Radiation Therapy - 3D-CRT - is a technique that uses uniform 
fields. The irradiation beams can be delivered from several directions: axial or non-
coplanar (Figure 8 - a). In the example of the figure, due to the uniformity of the 
beams, both tumour and spinal cord, are receiving the same dose limiting the 
prescription dose to the tumour. 
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Figure 8 - (a) 3D Conformal RT technique using uniform beams and (b) IMRT technique using non-
uniform beams [14]. 
Today, 3D conformal RT is performed using a multi-leaf collimator (MLC). The 
MLC is a device made of tungsten leaves that move independently from each other. 
These may be used to block normal tissues that are thus protected from the radiation 
beams (Figure 9). The movements of the multi-leaf collimator are computer-
controlled thus precisely delivering the treatment plan [14,15]. 
 
 
Figure 9 – Example of a Multi-leaf collimator (left) and MLC leaves positioned to protect both parotids 
from the radiation beam (right) [15,16]. 
Evolutions on external beam radiation therapy led to Intensity Modulated 
Radiation Therapy – IMRT - (Figure 8- b). Intensity modulated beams allow shaping 
the 3D dose distribution to concave tumour shapes and produce steep dose gradients 
in the target boundaries, thus significantly protecting the organs at risk compared to 
3D conformal radiation therapy. Thus target volume coverage and the sparing of the 
organs at risk are improved. Generally IMRT dose distributions are obtained using 
inverse treatment planning. In inverse optimization, after setting the desired clinical 
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objectives, for example the prescription dose in the target volumes and tolerance dose 
for the organs at risk, the inverse optimization algorithm will determine the fluency 
map that will produce the desired dose distribution [17-20]. 
The most common methods of delivery of IMRT are [15]: 
• Step-and-shoot or segmented – the collimator moves to a certain position 
and the radiation beam is switch on. When finished the irradiation the 
collimator will assume the next position until all segments are delivered 
(Figure 10); 
• Dynamic – based on a continue irradiation while the leaves of the collimator 
move continuously. 
 
 
Figure 10 – Example of a nine segments delivery by step-and-shoot method [21]. 
Image-Guided Radiation Therapy is a technique that allows to verify patient 
positioning while positioned in the treatment table. Two types of images can be 
acquired [22,23]: 
• 2D Portal images – the patient is irradiated with a very low dose from two 
orthogonal directions, one anterior and one lateral. This will create 2D 
images that will be compared with the corresponding CT planning image; 
• Megavoltage Cone-Beam CT – the linear accelerator rotates around the 
patient allowing the creation of a 3D image. This image is then compared 
with the planning CT and informs the position of the patient relatively to 
the isocenter. The cone-beam CT is normally used in more demanding 
treatment techniques (Figure 11). 
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Figure 11 – Megavoltage Cone-Beam CT [24]. 
	  
 
2.5 Dose-Response Models 
Dose-response models describe tissue response to radiation allowing to quantify 
cell survival rates and consequently the probability of tumour control or 
complications. Cellular death is proportional to the dose value that irradiates a certain 
tissue and depending on the dose delivered the tissues may be able to repair. To 
increase the repair of the normal tissues, radiation therapy is delivered in several 
fractions. The Linear-Quadratic Model assumes that the time between fractions is 
enough to repair sub-lethal damage. It describes the cellular survival rate (s) versus 
the delivered dose (D = number of fractions × dose per fraction): 
 𝑠 = 𝑒!(!"!!!!) 
 
where α/β quantifies the sensibility to fractionation related to the capacity of repair. 
Cells with a fast cellular cycle, e.g. skin or tumours, will express earlier effects, which 
translates into a high values of α/β. α/β=10 is normally used to describe those tissues. 
In other hand, tissues with a slow cellular cycle will manifest mostly late side-effects 
and generally have low α/β, i.e., α/β~3 (Figure 12). 
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Figure 12 – Linear-quadratic model for early and late responding tissues. A: high α/β value; B: low α/β 
value [25]. 
The Poisson-Linear-Quadratic model may then be applied to calculate the 
probability of response (P), which is described by the following expression: 
 𝑃 = 𝑒!!!! 
 
where N0 is the number of clonogens in case of tumours or the number of functional 
sub-units for organs at risk before the irradiation and s is the cellular survival rate 
calculated by the LQ models [25]. 
The probability of response may be described by several radiobiological models 
such as the Lyman and the Relative Seriality (Figure 13). Although, these are similar 
around the D50 value, differences between the models exist at low and high doses. 
 
 
Figure 13 – Dose-response curves for the Lyman (solid line) and Relative Seriality (dashed line) models 
derived for the breast complications [26]. 
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2.5.1 Lyman’s Model 
The classical Lyman’s model describes the probability of response in normal 
tissues or tumours, when an organ or tumour is uniformly irradiated. For normal 
tissues the probability of injury (PI) as a dose function (D), can be derived through the 
following integral probability: 
 𝑃! = 12𝜋 𝑒!!!/!𝜕𝑡!!!  
where 
 𝑡 = 𝐷 − 𝑇𝐷!"(𝑣)𝑚  ×  𝑇𝐷!"(𝑣) 
 𝑣 = 𝑉/𝑉!"# 
 𝐷!" 𝑣 = 𝐷!" 1   ×  𝑣!! 
 
D50(1) is the dose that causes 50% response if the organ was uniformly irradiated, v is 
the fraction of the organ that was irradiated, Vref is the reference volume for which D50 
was derived, m is the slope of the curve and n is the volume effect relationship. If n≈1 
the organ can be considered as having a parallel structure however if n≈0 it will be a 
serial structure [27-29]. 
Once this model can only be used for uniformly distributed dose irradiations, in 
case of a non-uniform distributions, the dose-volume histogram has to be transformed 
into a single dose value, i.e., equivalent uniform dose (EUD): 
 𝐸𝑈𝐷 = 𝑣!𝐷!!/!! ! 
 
where vi corresponds to the volume of the dose bin corresponding to the dose Di and n 
corresponds to the volume effect of the organ [30,31]. 
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2.5.2 Relative Seriality Model 
The Relative Seriality model corresponds to a radiobiological model that describes 
tissue response to radiation, allowing to calculate the probability of complications for 
a heterogeneous dose distribution. For normal tissues, the probability of injury (PI) to 
a certain organ that is irradiated with a certain dose distribution (𝐷) can be given by 
the expression: 
 
𝑃! 𝐷 =    1− 𝑃(𝐷!)!!!!!!!
!! ⇔ 
⇔   𝑃! 𝐷 = 1− (1− exp − exp 𝑒γ− 𝐷!𝐷!" . eγ− ln ln 2 !)∆!!!!!!
!!
 
 
where M is the number of voxels, Di is the dose in each voxel and Δvi (=ΔVi/Vref) is 
the fractional subvolume of an organ that is irradiated with dose Di. 
The parameters of the Relative Seriality model are [28,32]: 
• D50 - dose related to a 50% probability of complications; 
• γ - maximum normalized value of the dose-response gradient, i.e., 
corresponds to the slope of the curve; 
• s - quantifies the volume effect, assuming the values 0 or 1 for a parallel or 
serial organ, respectively. 
 
 
2.6 State of Art 
Marzi et al. [28], Shiltra et al. [33] and Houwling et al. [34] have derived dose-
response curves for the Relative Seriality model. These studies evaluated salivary 
flow compared with the pre-treatment one (objective measure) and/or evaluated the 
complications of the patients using questionnaires (subjective measure). The studies 
made focused in their majority the severities of complications G3 or G4. 
Marzi et al. [28] used the dose in both parotids in patients treated with IMRT and 
evaluated patient complications G3 in the follow-up times of 3, 6 and 12 months 
(Table 2). Marzi et al. [28] and Houwling et al. [34] obtained D50 values ranging from 
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38.8Gy to 40Gy, γ values from 0.80 to 0.95 and s value close to zero, reinforcing that 
the parotids are parallel structures. 
 
Table 2 - Summary of dose response parameters for the Seriality Model 
References	   Follow-­‐up	  Times	   D50	  [95%	  CI]	   γ	  [95%	  CI]	   s	  [95%	  CI]	   Additional	  Information	  
Schiltra	  C.	  	   13	  wk	   37.0	  [32.0-­‐46.0]	   2.00	  [1.00-­‐5.30]	   4E-­‐07	  [0.00-­‐0.19]	   Salivary	  flow,	  3D-­‐CRT	  
Marzi	  S.	  	  
3	  m	   20.0	  [16.7-­‐24.1]	   0.77	  [0.31-­‐1.42]	   0.01	  
G3,	  RTOG,	  IMRT	  6	  m	   26.3	  [21.5-­‐32.8]	   0.73	  [0.15-­‐1.55]	   0.01	  
12	  m	   40.0	  [32.0-­‐54.0]	   0.80	  [0.35-­‐1.62]	   0.01	  
Houweling	  A.	  	   12	  m	   38.8	  [36.5-­‐43.5]	   0.95	  [0.70-­‐1.30]	   0.08	  [0.00-­‐0.65]	   Salivary	  flow,	  IMRT,	  3D-­‐CRT	  
 
Dose-response parameters were also derived for the Lyman’s model by several 
authors as, for example, Marzi et al. [28], Roesink et al. [29], Shiltra et al. [33], 
Houwling et al. [34] and Dijkema et al. [35] (Table 3). D50 values obtained for both 
parotids at the follow-up time of 12 months ranged from 39.4Gy to 41.6Gy, m values 
from 0.36 to 0.45 and n values rounded the value 1, which in the Lyman’s model 
means that the parotids are parallel structures. 
 
Table 3  - Summary of some of the dose response parameters for the Lyman’s Model 
References	   Follow-­‐up	  Times	   D50	  [95%	  CI]	   m	  [95%	  CI]	   n	  [95%	  CI]	   Additional	  Information	  
Schiltra	  C.	  	   13	  wk	   38.0	  [33.0-­‐45.0]	   0.26	  [0.16-­‐0.34]	   1.30	  [0.30-­‐3.20]	   Salivary	  flow,	  3D-­‐CRT	  
Roesink	  J.	  	  
6	  wk	   31.0	  [26.0-­‐35.0]	   0.54	  [0.40-­‐0.78]	   1.00	  
Salivary	  flow,	  RTOG/EORTC,	  
3D-­‐CRT	  6	  m	   35.0	  [30.0-­‐40.0]	   0.46	  [0.34-­‐0.66]	   1.00	  
12	  m	   39.0	  [34.0-­‐44.0]	   0.45	  [0.33-­‐0.65]	   1.00	  
Marzi	  S.	  	  
3	  m	   21.4	  [18.4-­‐25.5]	   0.57	  [0.34-­‐1.37]	   1.00	  
G3,	  RTOG,	  IMRT	  6	  m	   27.8	  [23.6-­‐33.7]	   0.49	  [0.27-­‐1.42]	   1.00	  
12	  m	   41.6	  [32.8-­‐56.8]	   0.45	  [0.27-­‐1.49]	   1.00	  
Dijkema	  T.	  	   12	  m	   40.5	  [36.8-­‐44.1]	   0.36	  [0.28-­‐0.44]	   1.00	   G4,	  IMRT,	  dIMRT,	  Michigan	  (also	  values	  for	  Utrech)	  
Houweling	  A.	  	   12	  m	   39.4	  [33.8-­‐41.8]	   0.42	  [0.36-­‐0.58]	   1.13	  [0.75-­‐1.25]	   Salivary	  flow,	  IMRT,	  3D-­‐CRT	  
 
A study made by Eisbruch et al. [36] showed that the mean dose that should be 
delivered to the parotids should not overpass 26Gy, value that was embraced by other 
authors. 
This master thesis is focused in the Relative Seriality Model, although the data 
from other models was also collected. In this review all the parameters affecting the 
outcome, as for example the severity of complications studied, the type of follow-up 
used and the follow-up times studied were stored in an excel database (Appendix A). 
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CHAPTER 3: Materials & Methods 
3.1 Patients 
411 patients with head and neck tumours treated at IPOCFG from May 2007 to 
November 2013 were initially included in this study. Criteria for patient exclusion 
were: 
• very small number of follow-up appointments (11 patients); 
• G2 at the first consult. Such high severity in the first follow-up visit means 
that the patient already had complications that were not caused by radiation 
therapy (3 patients); 
• G4 complications (1 patient); 
• short follow-up time: RT treatment started after July 2013 (33 patients); 
• patients without dose information (25 patients). 
After the exclusion of 73 patients, a total of 338 patients remained. Patient’s 
characteristics for this group are shown in Table 4. The population gathered for this 
study presented an average age of 57.4±11.9 years (from 12 to 88) and average 
overall treatment time of 46±4.2 days. rIMRT (presented in Chapter 3.2) was the most 
used treatment technique to treat the population, 44%. 
 
Table 4 – Patient’s characteristics and number (n =338, population included in the study) 
Characteristics n (%) 
Gender 
   Female 
   Male 
 
56 (16.3) 
196 (83.7) 
Tumour type 
   Oral cavity 
   Oropharynx 
   Larynx 
   Nasopharynx 
   Pharyngeal-Laryngeal 
   Hypopharynx 
   Paranasal sinus 
   Others 
 
72 (21.3) 
68 (19.8) 
64 (19.2) 
42 (12.4) 
40 (11.5) 
27 (7.7) 
3 (0.9) 
22 (7.1) 
Characteristics n (%) 
T stage 
   TX 
   T1-2 
   T3-4 
 
8 (2.4) 
155 (46.5) 
168 (50.5) 
N stage 
   NX 
   N0-2a 
   N2b-3b 
 
8 (2.7) 
157 (46.8) 
168 (50.5) 
Technique 
   3D-CRT 
   dIMRT 
   rIMRT 
   IMRT 
 
36 (11.2) 
98 (28.4) 
150 (44.4) 
54 (16.0) 
CHAPTER 3: Materials & Methods 
 18 
3.2 Treatment 
At IPOCFG different radiation therapy techniques were used in the treatment of 
head and neck tumour cases. For each patient treatment selection was made according 
to the tumour type, tumour stage, age, general health status, etc. Since 2006 the 
techniques used were: 
• 3D Conformal Radiation Therapy (3D-CRT) - simple tumour cases (mostly 
stages I or II) are treated with up to 10 beam directions. In most cases only the 
primary tumour is outlined and the regional lymphatic nodes are not 
irradiated; 
• Direct IMRT (dIMRT) – forward planning using five to seven gantry 
directions with a total of 15 to 25 beams. In this technique each beam 
direction delivers at least three segments. The first segment irradiates the total 
target volume (PTV), the second irradiates the left side of the PTV sparing the 
spinal cord from irradiation, and the third one irradiates the right side of the 
PTV also sparing the spinal cord (Figure 14); 
• Inverse Planning – IMRT normally uses five to nine equidistant fields. It can 
be separated in two techniques according to the number of segments used: 
o Rapid IMRT (rIMRT) – uses around 30 to 55 segments; 
o IMRT – uses 56 to 80 segments. Requires extensive patient specific 
quality control limiting the utilization of this technique to most 
difficult tumour cases. 
 
 
Figure 14 – Example of three segments of a dIMRT treatment: the first irradiates the total PTV (PTV-
N1, which includes the PTV-T and the adenopathies, and PTV-N2); the second and third segments irradiate 
the left and right side of the PTV, respectively, protecting the spinal cord from being irradiated [courtesy of 
IPOCFG]. 
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The commercial treatment planning system used is ONCENTRA 
(Elekta/Nucletron) and treatment delivery is performed in a Siemens Oncor Avant-
Garde linear accelerator. 
 
 
3.3 Dosimetry 
Most radiation therapy treatments were delivered by a sequence of two or three 
plans, where the total delivered dose is given by the sum of the dose of all plans. 
However, for radiobiological modelling the total physical dose needs to be converted 
to an equivalent 2Gy fractionation because all radiobiological models were derived 
for that fractionation. For that, the structures, plans and dose matrix of all patients 
were manually exported from the ONCENTRA. Additional patient information was 
exported from LANTIS (Siemens), the Record & Verify data network, and imported 
into RESPONSE (UA/IPOCFG), an electronic health patient information software 
developed by Aveiro University in collaboration with IPOCFG. In cases where the 
radiation therapy was suspended, total dose was corrected for treatment interruptions. 
Total delivered dose was corrected for a 2Gy fractionation using the Biologically 
Effective Dose concept, BED, which converts the 3D dose distribution of each 
treatment plan into a 2Gy fraction dose for each voxel: 
 
𝐵𝐸𝐷 = 𝐷! 1+ 𝑑!𝛼𝛽
!!
! = 𝐷!!" 1+ 2𝛼𝛽  
 
in this equation Np is the number of plans, Di is the physical dose in each voxel of the 
dose distribution i, di is the dose per fraction in each voxel and α/β is the ratio of the 
Linear-Quadratic model which assumes the value 3 for late effects in normal tissues 
and 10 for early effects. 
The total delivered dose corrected into the 2Gy fractionation allow to calculate 
dose-volume histograms and dose statistics for all the regions of interest such as 
mean dose and DBB. 
The biologically effective uniform dose - 𝐷 or DBB – is a dose quantity that takes 
into account the real dose distribution (3D dose matrix) as well as the biological 
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characteristics of the structure, i.e., their radiosensitivity. Thus this value describes 
more accurately tissue response to radiation. The DBB can be calculated through the 
following expression [25,37,38]: 
 
𝑃 𝐷 = 𝑃 𝐷 ↔ 𝐷 = 𝐷!" 𝑒𝛾 − ln  (− ln 𝑃 𝐷 )𝑒𝛾 − ln  (ln 2 )  
 
 
 
3.4 Dose-Response Curves 
In this study dose-response curves were derived for the Relative Seriality model. 
The study was made considering the dose delivered into the structures: contralateral 
parotid, ipsilateral parotid, sum of the parotids and salivary glands (Figure 15). The 
contralateral parotid corresponds to the parotid in the opposite side of the primary 
tumour so it receives less dose than the ipsilateral parotid. The sum of the parotids is 
a structure that includes both parotids. Two groups of salivary glands were created 
because some patients were operated and did not have one of the submandibular 
glands: 
• Salivary Glands-5 – includes the ipsilateral parotid, contralateral parotid, 
oral cavity and both submandibular glands; 
• Salivary Glands-4 – contains all the above structures except the ipsilateral 
submandibular gland. 
 
 
Figure 15 – Structures and follow-up times studied. 
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Patient’s follow-up at IPOCFG consists on weekly visits during treatment that 
take about seven weeks. After that the patients have appointments every three months 
during two to three years and later every six months. The severity of complications 
were classified according to RTOG/EORTC guidelines (Table 1). Because at 
IPOCFG patients have continuous follow-up appointments, it was possible to derive 
dose-response curves for different times after the radiation therapy treatment. Periods 
evaluated were 7 weeks, 3, 7, 12, 18 and 24 months (Figure 15). 
 
 
3.5 Maximum Likelihood Model 
The Maximum Likelihood Model is the method used to find the best combination 
of radiobiological parameters for, in this case, the Relative Seriality model. The 
maximum likelihood function (L) is model related so it is calculated in order to D50, 
γ and s, taking into account the radiosensitivity of the tissue (𝑋) and the treatment 
delivered to the patient (𝜃): 
 𝐿 𝑋\𝜃 = 𝐿 𝐷!", 𝛾, 𝑠 , 𝐷,𝑉 ⇔ 
⇔ 𝐿 𝑋\𝜃 = 𝑃( 𝐷!", 𝛾, 𝑠 , 𝐷!,𝑉! )× (1− 𝑃 𝐷!", 𝛾, 𝑠 , 𝐷!,𝑉! )!!!!!!!!  
 
where 𝐷 is the dose delivered during treatment, 𝑉 is the corresponding tissue volume 
receiving that dose, and m and n are the numbers of patients with and without 
complications, respectively. 
With the values of the maximum likelihood function, the best radiobiological 
parameters and their confidence intervals can be determined by fitting the normal 
tissue response probability in order to D50 and γ. If all the D50 and γ possibilities were 
calculated that would create a 3D curve  where each point would correspond to a 
combination of parameters (Figure 16). Since in practice not all the possibilities are 
calculated it is necessary to repeat the fitting process several times using a different 
set of initial guesses for D50 and γ to guarantee that the combination that maximizes L 
was found (maximum point of the 3D curve) [32,33,39]. 
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Figure 16 – Example of the curve expected for a probability of injury (P) as a function of the 
parameters D50 and γ s for a fixed s value of 0.01 [33]. 
 
 
3.6 Goodness of the Fit 
There are several methods that statistically analyse the goodness of the fit. In this 
study the Receiver Operating Characteristic (ROC) curve, the Pearson’s X2-test and 
the Worst-fit were used. 
 
3.6.1 ROC Curve 
A model is considered useful in case it efficiently separates responders (patients 
with complications) from non-responders (complication-free patients). The Receiver 
Operating Characteristic curves (ROC curves) use the Relative Seriality model 
parameters to evaluate the reliability of the model through the discrimination between 
patients with complications and complication-free. 
ROC curves can be generated through the plotting of the true positive ratio (TPR) 
versus the false positive ratio (FPR) (Figure 17). To calculate the true and false 
positive ratios the population is sorted by their probability of complications and then 
the observed responses above the trial cutoffs (Pcut) is compared with the number of 
expected responses. The true positive ratio corresponds to the number of correct 
positive results above Pcut (TP) that occur among all positive samples, i.e., sensitivity: 
 𝑇𝑃𝑅 = 𝑇𝑃𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒  𝑆𝑎𝑚𝑝𝑙𝑒𝑠 
point that 
maximizes L 
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The false positive ratio quantifies the number of incorrect positive results above the 
Pcut (FP) that occur among all negative samples, i.e., 1-specificity: 
 𝐹𝑃𝑅 = 𝐹𝑃𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒  𝑆𝑎𝑚𝑝𝑙𝑒𝑠 
 
The plot of true positive ratio versus false positive ratio will create a curve where 
the Area Under the Curve (AUC) will quantify the ability of the test to discriminate 
responders and non-responders. In case of AUC=1 that means that there is an optimal 
discrimination between complications and complication-free patients. If AUC=0.5, 
which happens when TPR=FPR, that means that the prediction is random. For 
example in Figure 17 C corresponds to a random result (AUC=0.5), D to the ideal 
situation (AUC=1) and E is considered worse than guessing (AUC<0.5). Thresholds 
to separate good from very good from reasonable are still discussed among different 
authors. In this study the evaluation of the area under the curve was made through the 
following ranges [32,40,41]: 
• very good: 0.8 - 0.9; 
• good: 0.7 - 0.8; 
• reasonable: 0.6 - 0.7; 
• poor: <0.5. 
 
 
Figure 17 – Example of a ROC curve [adapted from 40]. 
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3.6.2 Pearson’s X2-test 
Pearson’s X2-test is a statistical method that studies the spread of data points 
(complications and complication-free). The Pearson’s statistical test approaches a X2 
distribution, which can be calculated through the following expression: 
 𝑋! = (𝑂! − 𝐸!)!𝐸!!!!!  
 
where Ei is the expected frequency, n is the total number of dose ranges and Oi is the 
observed frequency. 
To execute the Pearson’s X2-test it is necessary to achieve a good approximation of 
the X2 distribution, which can be made through the comparison of the value from the 
X2 distribution with the degrees of freedom (df). The degrees of freedom are 
calculated through: 
 𝑑𝑓 = 𝑛 − (𝑠 + 1) 
 
where s corresponds to the number of co-variants used in fitting the distribution, 
which in our case correspond to the three radiobiological parameters, i.e., df=n-(3+1). 
The spread can be considered as a good distribution if the X2 distribution divided 
by the number of degrees of freedom (=X2/df) is reasonably large, i.e., close to 1. 
However, if the value is small, that could mean that the data doesn’t make a good 
representation of the distribution or that the theoretical distribution does not estimate 
well the observed distribution, i.e., actual data [42,43]. 
 
3.6.3 Worst-fit 
The Worst-fit probability is based on the assumption that the log-likelihood 
function describes a Gaussian distribution and considers the variance magnitude 
through the comparison between the mean and maximum values of ln(L). For the 
goodness of the fit to be considered optimal, a good agreement between the 
CHAPTER 3: Materials & Methods 
 25 
prediction and clinical results distributions must be achieved through a large 
probability, i.e., close to 1 [39]. 
 
3.6.4 Tolerance Dose 
The tolerance dose corresponds to the threshold that separates complication-free 
patients from patients with complications. This dose value has an odd ratio (OR) 
associated, which represents the risk of patients developing complications in case of 
the threshold being overpassed. 
The odd ratio corresponds to a statistical quantifier of the strength of the 
association between the complications and complication-free patients. This value can 
only be considered as statistical significant when the lower limit of the 95% 
confidence interval (CI) is equal or higher than 1. In case of being lower than 1 the 
association is bad and cannot be considered as significant [32]. 
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CHAPTER 4: Results 
4.1 Dose-Volume Histograms Analysis 
Dose-volume histograms (DVH) show the percentage of the irradiated volume 
versus the dose delivered in each structure. In clinical practice generally cumulative 
dose-volume histograms are used for treatment plan evaluation. Using the dose-
volume histograms of all treated patients, mean DVH for patients treated with 
different techniques or having different treatment outcomes were calculated. For that 
different MATLAB functions were developed (Appendix B). 
Figure 18 shows the mean dose-volume histograms of the contralateral parotid for 
patients treated with different techniques. Although it was expected that the mean 
dose-volume histograms for IMRT should present lower dose, this is not seen because 
this technique is used to treat most difficult tumour cases. By contrary, 3D-CRT 
technique has the lowest dose values because it is used to treat the simplest cases. 
Furthermore, the beam configuration used in 3D-CRT is completely different than for 
IMRT because of the different PTV shapes. Thus, patients treated with 3D-CRT were 
excluded from the study (36 patients) to consider only patients that were irradiated 
similarly. 302 patients were considered as the final population of the study. With 
IMRT and rIMRT a smaller volume of the structure is irradiated with higher dose 
while a larger amount of tissue is irradiated with lower doses. 
 
 
Figure 18 – Mean dose-volume histogram for the contralateral parotid for different treatment 
techniques. 
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Figure 19 shows the mean dose-volume histograms for the contralateral parotid 24 
months after radiation therapy (thicker curve). The black curves show the DVH for 
each patient. The first, second and third plots display the dose-volume histograms for 
patients with complications G0, G1 and G2, respectively. Nc shows the number of 
patients in each group. As expected the mean DVH for G0, i.e., for the group of 
patients complication-free, had lowest dose values when compared to the other two. 
However, mean curves for G1 and G2 are almost overlapped. Thus, two studies were 
made where patients were grouped as showed in Figure 20. 
 
 
Figure 19 – Mean dose-volume histograms calculated for patients with endpoints G0, G1 and G2 for the 
contralateral parotid, twenty-four months after the radiation therapy treatment. 
 
      
Figure 20 – Both ways of grouping the patients: G0 vs. G1+G2 and G0 vs. G2. 
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4.2 G0 vs. G2 
Figure 21 to 27 show some of the dose-response curves derived for xerostomia G2 
when the dose in the parotid glands was considered, as well as the correspondent 
ROC curves. Dose-response curves were derived for all structures and follow-up 
times, as well as the respective ROC curves for the group G0 vs. G2 can be seen in 
Appendix C.1. 
In the left side of the Figure 21 the DRC derived for the ipsilateral parotids 12 
months after radiation therapy (solid line), as well as their 68% confidence interval 
(both dashed lines) are presented. The crosses correspond to patients with 
complications and the circles correspond to the patients without complications. The 
squares show the percentage of patients with xerostomia G2 in each dose range and 
the error bars represent the dose standard deviation. For example, 55% of the 
ipsilateral parotids irradiated with around 48Gy reported complications G2. Since the 
discrepancy between the clinical points and the model is not that big that means that 
the model represents well the clinical data. In the right side of the Figure 21 the ROC 
curve derived for this DRC is shown. The area under the curve is 0.69 indicating a 
model of reasonable quality (range 0.6 to 0.7). 
 
 
Figure 21 - DRC (left) and correspondent ROC curve (right) for the ipsilateral parotid 12 months after 
the RT for the group G0 vs. G2.   
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Figure 22 to 27 show the DRC and respective ROC curves for all the follow-up 
times studied when the structure under analysis was the contralateral parotid. From 
these figures it can be shown that in general the model follows very closely the 
clinical points. Supporting the quality of de model are the values of AUC ranging 
from 0.620 to 0.715 and the values of the Worst-fit ranging from 0.601 to 0.611 
(Table 6 and 7, respectively). However, some discrepancies were obtained. For the 
follow-up time 7 weeks although the model follows very closely the clinical data, the 
model estimate a probability of complications of 25% for patients that were not 
irradiated (Figure 22). This questions the quality of the model for very low doses 
since patients that started treatment already with complications were excluded from 
the study. This may mean that the algorithm that optimizes the radiobiological 
parameters was trapped in a local maximum and the maximum of the L function was 
not reached. The low γ value indicates that this may have happened. In Figure 24 the 
clinical point corresponding to 40Gy is outside the confidence interval of the DRC. 
This may be related to the low number of patients included in this point (N=2), 
leading to the conclusion that the point is not very reliable. 
 
 
Figure 22 – DRC (left) and correspondent ROC curve (right) for the contralateral parotid 7 weeks after 
the RT, for the group G0 vs. G2. 
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Figure 23 - DRC (left) and correspondent ROC curve (right) for the contralateral parotid 3 months after 
the RT for the group G0 vs. G2. 
  
Figure 24 - DRC (left) and correspondent ROC curve (right) for the contralateral parotid 7 months after 
the RT for the group G0 vs. G2. 
 
Figure 25 - DRC (left) and correspondent ROC curve (right) for the contralateral parotid 12 months 
after the RT for the group G0 vs. G2. 
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Figure 26 – DRC (left) and correspondent ROC curve (right) for the contralateral parotid 18 months 
after the RT for the group G0 vs. G2. 
  
Figure 27 - DRC (left) and correspondent ROC curve (right) for the contralateral parotid 24 months 
after the RT for the group G0 vs. G2. 
The radiobiological parameters, D50, γ and s, calculated for G0 vs. G2 for the 
contralateral parotid for increasing follow-up time can be compared in Table 5. The 
same results for all structures showed and follow-up times are in Appendix D.1. As 
the follow-up time increases also the D50 value does. This is because there is a 
decrease of the complications with time (Figure 28) due to the capacity of 
regeneration of the healthy tissues with time after irradiation. For example 23% of 
patients at the 24th month of follow-up remained with xerostomia G2 compared to 
78% at the 7th week. 
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Table 5 – Relative Seriality model parameters for the contralateral parotids, G0 vs. G2 
Follow-up 
Times 
Nb. 
Patients D50 [68% CI] (Gy) γ [68% CI] s 
7 wk 135 9.6 [8.6-10.6] 0.150 [0.045-0.225] 0.008 
3 m 74 22.6 [20.3-35.6] 0.224 [0.067-0.381] 0.056 
7 m 54 32.2 [29.0-35.4] 0.609 [0.183-1.035] 1x10-4 
12 m 112 38.6 [34.7-42.5] 0.707 [0.212-1.202] 1x10-4 
18 m 85 51.7 [46.5-56.9] 0.444 [0.133-0.755] 1x10-4 
24 m 68 48.3 [43.5-53.1] 0.685 [0.206-1.165] 1x10-4 
 
 
 
Figure 28 - Evolution of the number of patients (%) in the complications group (G2) through the follow-
up time. 
A recurrent problem in this study was the low γ value obtained for the dose-
response curves of the salivary glands (including 4 and 5 structures) at the 3rd month 
after the radiation therapy treatment. This may be related to the fact that although 
some patients were irradiated with low DBB values they developed complications. 
The low γ values may be related to the clinical history of these patients, e.g. a 
previously disease leading to a higher radiosensitivity of the patient and so to a higher 
damage of the healthy tissues, preventing the recovery of the complications 
developed with the radiation therapy treatment. Due to this low γ values further 
analysis of these models were not made. 
The last radiobiological parameter of the model, s, is approximately zero 
confirming that the parotids are parallel organs, i.e., that a small part of the parotids 
may be irradiated with a dose above the tolerance dose and organ functionality is not 
lost if the remaining organ is protected. 
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Table 6 and 7 summarizes the values obtained for the AUC and Worst-fit for all 
dose-response curves, respectively. The goodness of the fit evaluated using the 
methods: ROC curves, Pearson’s X2-test and Worst-fit are in Appendix E.1 for every 
structure and follow-up time. Considering AUC values, the best dose-response 
parameters are those derived for the follow-up times 12, 18 and 24 months when 
considering the dose in the contralateral parotid and parotids sum. Using the Worst-fit 
model to test the goodness of the fit (Table 7), values around 0.60 were obtained for 
all cases. This means that the dose-response curves are of reasonable quality. 
 
Table 6 – AUC values (%) for the DRC derived for G0 vs. G2. 
Follow-up 
Times 
Contralateral 
Parotid 
Ipsilateral 
Parotid Parotids Sum 
Salivary 
Glands_4 
Salivary 
Glands_5 
7w 62.01 64.41 62.81 65.13 63.66 
3m 65.74 66.10 65.93 - * - * 
7m 68.47 67.40 67.94 67.43 65.46 
12m 69.93 69.18 69.37 67.24 66.28 
18m 71.45 68.51 70.25 68.48 67.32 
24m 70.64 67.11 69.14 65.75 64.63 
*Due to the poor quality of the γ value, these models were rejected in this study. 
 
Table 7 – Worst-fit values (%) for the DRC derived for G0 vs. G2. 
Follow-up 
Times 
Contralateral 
Parotid 
Ipsilateral 
Parotid Parotids Sum 
Salivary 
Glands_4 
Salivary 
Glands_5 
7w 60.11 60.11 60.11 60.11 60.11 
3m 60.37 61.30 61.02 - * - * 
7m 61.08 60.96 61.70 60.45 60.19 
12m 60.54 60.31 60.48 60.22 60.15 
18m 60.49 60.12 60.23 60.44 60.32 
24m 60.11 60.11 60.11 60.11 60.11 
*Due to the poor quality of the γ value, these models were rejected in this study. 
 
The mean DBB used to plot all dose-response curves from this study, in the 
contralateral parotid and sum of the parotids for patients with complications and 
complication-free was calculated (Figure 29). The mean DBB values for the other 
structures may be seen in Appendix F.1. Figure 29 shows the mean DBB values and 
standard deviation for patients that developed complications (circles) and those that 
did not (squares) for all follow-up times studied. The threshold value, above which 
patients have a higher risk to develop complications, is also presented (stars). 
Generally, patients that developed complications received a higher dose than those 
that had no side-effects, dose value that is around 26Gy (confirms the study of 
Eisbruch et al. [27]). For patients with complications mean DBB was approximately 
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33Gy. Considering the dose in both parotids, mean DBB values for the group of 
patients complication-free and with complications received around 28Gy and 34Gy, 
respectively. To note that the difference between the values of both structures is not 
that significant as indicated by their standard deviation. The threshold or tolerance 
dose for the contralateral parotid at the follow-up time of 12 months was 28Gy, i.e., 
for patients receiving dose higher than 28Gy the risk of developing complications 
was 3.85 (95% CI: 1.19-12.47) times higher than patients that received doses lower 
than 28Gy. Once the lower value of the confidence intervals was higher than 1, the 
odd ratio can be considered as statistically significant. The same threshold dose was 
obtained for a follow-up time of 12 months when considering the dose in the sum of 
the parotids. However, the risk of developing complications is a bit higher, 4.57 (95% 
CI: 1.60-13.10) times higher than patients that received lower doses. 
 
  
Figure 29 - Mean DBB values and respective standard deviation for the complication-free (G0) and 
complications (G2) groups for the contralateral parotid (left) and sum of the parotids (right). The threshold 
dose above which patients had a higher risk to develop complications is also shown. 
 
 
4.3 G0 vs. G1+G2 
Figure 30 to 33 show some of the dose-response curves derived for xerostomia 
G1+G2 for different structures 24 months after RT, as well as the correspondent ROC 
curves. Dose-response curves and respective ROC curves derived for G1+G2 
xerostomia are presented in Appendix C.2 for every structure and follow-up time 
studied. 
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In the left side of the Figure 30 the dose-response curve derived for the 
contralateral parotids at the 24th month of follow-up (solid line) is presented. 
Qualitatively, the model represents well the clinical data. Quantitatively, if the 
contralateral parotid is irradiated with 22Gy the model predicts a 27% probability of 
complications, while the incidence of complications for this dose is 31%. The ROC 
curve is presented above the line that shows random predictions, i.e., where the true 
positive ratio is equal to the false positive ratio (TPR=FPR). The area under the curve 
in this case was 0.67 what is considered a reasonable model. 
 
 
Figure 30 – DRC (left) and correspondent ROC curve (right) for the contralateral parotids 24 months 
after the RT for the group G0 vs. G1+G2. 
Figure 31 to 33 show the DRC and respective ROC curves derived for the 24th 
month after the RT studied when the structures under analysis were the sum of the 
parotids and the salivary glands with 4 and 5 structures. From these figures it can be 
shown that for both salivary glands the models do not follow the clinical points so 
well and so this situations need to be revaluated. 
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Figure 31 - DRC (left) and correspondent ROC curve (right) for the parotids sum 24 months after the 
RT for the group G0 vs. G1+G2. 
  
Figure 32 - DRC (left) and correspondent ROC curve (right) for the salivary glands with 4 structures 24 
months after the RT for the group G0 vs. G1+G2. 
  
Figure 33 - DRC (left) and correspondent ROC curve (right) for the salivary glands with 5 structures 24 
months after the RT for the group G0 vs. G1+G2. 
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The radiobiological parameters for the contralateral parotid when patients were 
grouped as G0 vs. G1+G2 are presented on Table 8. The relative seriality parameters, 
D50, γ and s, calculated for G1+G2 xerostomia for all the structures and follow-up 
times are presented on the Appendix D.2. As before, D50 increases with follow-up 
time and s≈0. Models with very low γ values (γ<1x10-2) were rejected in this study, 
i.e., the models for the 7th week and 3rd month of follow-up time of all the structures 
studied. 
 
Table 8 – Relative Seriality model parameters for the contralateral parotids, G0 vs. G1+G2 
Follow-up 
Times 
Nb. 
Patients D50 [68% CI] (Gy) γ [68% CI] s 
7 wk 291 4.0 [3.6-4.4] 1x10-4 [0.3x10-4-1.7x10-4] 0.039 
3 m 171 7.1 [6.4-7.8] 1x10-4 [0.3x10-4-1.7x10-4] 0.139 
7 m 97 20.6 [18.5-22.7] 0.429 [0.129-0.729] 0.026 
12 m 188 23.1 [20.8-25.4] 0.247 [0.074-0.420] 3.3x10-4 
18 m 145 24.8 [22.3-27.3] 0.225 [0.068-0.383] 1x10-4 
24 m 98 33.6 [30.2-37.0] 0.547 [0.164-0.930] 0.026 
 
Table 9 show the values obtained for the AUC for the dose-response curves of 
G1+G2 xerostomia. The values quantifying the goodness of the fit for this group is 
shown in Appendix E.2 for every structure and follow-up time. The best dose-
response curves were for the follow-up times of 12, 18 and 24 months when it is 
considered the dose that reaches the contralateral parotid and parotids sum. However, 
when comparing these results with those obtained for G2 xerostomia it can be noticed 
that the AUC of G0 vs. G2 were about 0.70 and for the G0 vs. G1+G2 the AUC 
values approximate 0.66. This leads to the conclusion that the models derived for G2 
xerostomia have a higher prediction ability than for G1+G2 xerostomia. 
 
Table 9 - AUC values (%) for the DRC derived for G0 vs. G1+G2. 
Follow-up 
Times 
Contralateral 
Parotid 
Ipsilateral 
Parotid Parotids Sum 
Salivary 
Glands_4 
Salivary 
Glands_5 
7m 64.84 65.73 65.31 65.53 65.53 
12m 66.06 66.18 66.19 66.11 65.87 
18m 66.03 66.03 66.05 66.04 65.74 
24m 66.47 66.97 67.55 66.97 66.13 
 
The mean DBB values that differentiate patients with complications from 
complication-free were calculated and are shown in Figure 34 for the contralateral 
parotid and sum of the parotids. The corresponding DBB values for the other 
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structures may be seen in Appendix F.2. Complication-free patients had mean DBB 
values in the contralateral parotid around 27Gy and patients with complications 
received approximately 32Gy. For the sum of the parotids complication-free and 
complications groups received around 29Gy and 33Gy, respectively. However 
caution is advised since the difference between the values of both structures is not 
that significant. The threshold dose for the contralateral parotids 24 months after the 
RT was 26Gy. Patients receiving higher dose values at the contralateral parotids have 
a risk of developing complications 4.47 (95% CI: 1.51-13.24) times higher than 
patients that received lower doses. This result was statistically significant. In other 
hand, the threshold dose in the sum of the parotids for the same follow-up time was 
39Gy, with a risk of developing complications of 4.14 (95% CI: 1.52-11.24) 
compared to patients receiving lower doses. 
 
  
Figure 34 - Mean DBB values and respective standard deviation for the complication-free (G0) and 
complications (G1+G2) groups for the contralateral parotid (left) and sum of the parotids (right). 
Threshold dose shows the tolerance dose above which patients had a higher risk to develop complications. 
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treatment still calculate physical dose in most of the cases. Thus the relation between 
DBB and the mean dose (Dmean) in the contralateral parotids was studied (Figure 35) 
for the follow-up times 12 and 24 months. It can be seen that the relation between 
DBB and mean dose values is almost linear (slope of the curve is approximately 1) 
but both dose measures are not equal. Both follow-up time’s data are overlapped and 
both linear tendencies have a R2≈1. Due to that, it can be concluded that the DBB 
values are almost proportional to the mean dose values and they are time 
independent. 
 
 
Figure 35 – Comparison of the DBB with the mean dose (Dmean), for the contralateral parotids, 12 and 
24 months after RT. 
 
y = 0,9857x 
R² = 0,95089 
y = 0,9826x 
R² = 0,95357 
0 
10 
20 
30 
40 
50 
60 
0 10 20 30 40 50 60 
D
m
ea
n/G
y 
DBB/Gy 
12m 
24m 
Linear 
(12m) 
Linear 
(24m) 
CHAPTER 5: Discussion 
 41 
CHAPTER 5: Discussion 
5.1 Comparison of Endpoints 
Figure 36 shows the dose-response curves derived for the contralateral parotid, 
sum of the parotids and salivary glands with 4 structures at the 18th month of follow-
up, for both the groups G0 vs. G2 and G0 vs. G1+G2. From the figure, it can be seen 
that when low severities of complications, e.g. G1, are included in the model the 
curves shift to the left because low severities are related to low dose values received 
during the radiation therapy treatment. However, Figure 36 show that the 
radiobiological parameters derived for xerostomia G2 are better than the ones derived 
for xerostomia G1+G2, since at 0Gy a 0% probability of complications is estimated. 
 
 
Figure 36 – DRC for follow-up time of 18 months: G0 vs. G1+G2 (solid curves) and G0 vs. G2 (dashed 
curves).  
 
 
5.2 DRC for Different Structures 
Dose-response curves for different structures are compared for different follow-up 
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group G0 vs. G1+G2 are very close. In this case only the parotids may be used to 
estimate the probability of xerostomia in a patient. However, the models derived for 
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outlined (32 for the SG with 4 structures and 24 for the SG with 5 structures), which 
may affect the DRC shape. Further studies are needed to better understand this 
difference. 
 
 
Figure 37 – DRC for different structures, 7 months after RT. CP: contralateral parotids, IP: ipsilateral 
parotids, PS: parotids sum, SG_4: salivary glands with 4 structures, SG_5: salivary glands with 5 
structures. 
 
 
5.3 DRC for Different Follow-up Times 
In Figure 38 the DRC for the parotids sum are presented for G0 vs. G2 and G0 vs. 
G1+G2. The dashed lines show acute complications (≤6 months) while solid lines 
show late complications (>6 months). As also seen in Table 5 (G0 vs. G2) and Table 
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Figure 38 – DRC of the parotids sum (ipsilateral + contralateral) for different follow-up times. 
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Figure 39 – Comparison of the published DRC for the Relative Seriality Model (dashed lines) with the 
DRC derived in this study for parotids sum of G0 vs. G2 (solid lines). Radiobiological parameters Marzi et. 
al. etc. (right). 
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CHAPTER 6: Conclusions 
 
The dose-response parameters that may give the best prediction of the probability 
of xerostomia were obtained for the follow-up times of 12, 18 and 24 months when 
considering the dose in the contralateral parotid and/or the sum of the parotids. 
Furthermore, the predictive ability of the model is better for xerostomia G2 than for 
xerostomia G1+G2. 
 
As the follow-up time increases, DRC move towards high D50 values. γ values 
range from 0.1 to 0.7. The radiobiological parameter s confirms the fact that the 
parotids are parallel structures. 
 
Patients irradiated in the contralateral parotid and in the sum of the parotids with a 
mean dose values higher than 28Gy have a risk of developing xerostomia G2 3.85 
and 4.57 times higher than if receiving lower dose values, respectively. 
 
Xerostomia is a consequence of damages in all salivary glands. However, the dose 
in both parotids may be a good surrogate to estimate the probability of G2 
xerostomia. Unfortunately, given the small number of patients used to derive the 
dose-response curves for the salivary glands, further studies may be needed to 
confirm the results obtained. 
 
Model validation using a different patient population must be made before the 
model derived in this study may be used clinically. 
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Appendix A – Review from the Literature 
Summary of the papers related to the salivary glands that report xerostomia as a 
complication. 
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\  
Tumour Planning
Score Scoring Criteria Guideline Nº of Patients (N) Age Sublocation Duração
Total dose 
(Gy)
Dose/fracti
on (Gy) Technique Fields
Energy 
(MV) TPS
Pre-RT 
Treatments
Concomitant 
chemotherapy
Date of 
treatments
Mean Objective Subjective
2 4 Severe=decrease in stimulated salivary flow <25% of the pre-RT value RTOG 88 55
Oral cavity, oropharynx, 
nasopharynx, larynx, salivary 
glands, skin, others
1 year after RT measurement of salivary flow 64  (57,6–72) 1,8-2 3DCRT, IMRT
3DCRT: 7 to 8 fields, sometimes are used 
electron irradiation fields  for the posterior 
cervical
6, 15, 9 MeV 
and 12 MeV U-Mplan
Surgery, 
Chemotherap
y
March of 1994 
to Augost of 
1997
6 weeks after 
RT
6 months after 
RT
1 year after RT
5 2 RTOG 23
Oral cavity, oropharynx, 
nasopharynx, larynx, 
hipopharynx
14,8 months (8-
26 months)
Measurment of the 
salivary flow with and 
without estimulation
50 (PTV1), 10 
to 20 (PTV2) 2 IMRT
7 to 8 fields and 1-15 segments by field (step 
and shoot) 6,15 Helax TMS Surgery
April 2000 to 
December 
2001
6 65 57
Oral cavity, oropharynx, 
nasopharynx, larynx, pharynx, 
others
up to 1 year 
after RT
measurment of the 
salivary flow questionaires 50,4 to 72 1,8 to 2 3DCRT, IMRT
CMS (RTC-
3D), 
Peacock 
Planner 
(IMRT)
Surgery, 
chemotherapy Yes
February 1997 
to September 
2000
92 54 60-75 1,8-2,0 Forward-planned, inverse-planned and beamlet IMRT 1994-2005
130 58 50-70 , 69-70 2 , 2,0-2,3 CRT (opposing lateral beams), inverse-planned IMRT 1996-2007
13
stimulated salivary 
flow rates 
measurement using 
Lashley cups
1 year after RTfow ratio <25% of the pre-RT flow rate4 RTOG/EORTC 60 Surgery: Y/N69-70 1999-July 2012
1
3DCRT 2 laterally opposed fields and an AP field 6 Helax TMS Surgery3 decrease in stimulated salivary flow to <25% of the pre-RT value 15
Surgery
4 decrease in stimulated salivary flow to <25% of the pre-RT value
RTOG/EORTC 
Late Effects 
Consensus
Conference
7 4 Decrease in stimulated salivary flow to <25% of the pre-RT value 52 56 57 months 
(44–72)
stimulated parotid 
saliva using Lashley 
cups placed over the 
orifice of the parotid 
duct
10 3
0 = none; 1 = slight dryness of mouth, good response to stimulation; 2 
= moderate dryness of mouth, poor response to stimulation; 3 = 
complete dryness of mouth, no response to stimulation; 4 = fibrosis
RTOG 59 57,5 Nasopharynx, oropharynx, hypopharynx, oral cavity yes70 IMRT
5 to 7 fields, ensuring, whenever achievable, 
that each parotid did not receive a mean dose 
>32 Gy
Cadplan; 
Eclipse
12,8 months 
after RT 
(2,8–29,3)
measurements of 
salivary excretion 
fraction by 
scintigraphy or saliva 
collection
quality-of-life 
questionnaires 
(the patient's 
subjective 
perception of 
xerostomia)
151
Larynx, Hypopharynx, 
Oropharynx, Nasopharynx, 
Oracl cavity, Unknown primary
measurement of 
simulated individual 
parotid gland flow 
rates before and after 
RT using Lashley 
cups after applying 
citric acid solution (2-
5%) on the mobile 
part of the tongue
1 year after RT
60
0: no effect on speech or swallowing; 1: speech requires some effort; 
smallowing requires some effort but without need to be supported by 
fluid intake; 2: discomfort in speaking and swallowing with need for 
fluid intake; 3: need for fluid intake for regular conversation; 4: dry 
oral mucosa
25 52,4 3DCRT opposed lateral fields or 3 fields
No No
Oropharynx, nasopharynx, 
lynphoma (Waldeyer's ring)
2,3-36,6 
months
Scintigraphy 
(measurement of 
salivary flow)
30-70 2,3-2,5
46 - 70 2until the 13th week after RT
measurements of 
salivary excretion 
fraction by saliva 
collection
108 57
Larynx, oropharynx, oral 
cavity, nasopharynx, nose, 
hipopharynx, unknown, others
measurement of 
salivary flow 46-70 2 3DCRT
Opposed lateral fields with spinal cord 
protection up to 40-46 Gy; electron fields for 
boost in the posterior neck region; 
supraclavicular regions irradiated with hemi-
previous field
6 Plato
Prescribed Dose
Assessment
Other treatmentsFollow upPopulation
Pa
pe
rs
Complication for each individual gland was defined as a stimulated 
parotid flow eatio <25% on the pre-RT flow rate4
222
Larynx, Hypopharynx, 
Oropharynx, Nasopharynx, 
Oracl cavity, Nasalcavity, 
Salivary Glands, Unknown n 
primary, Other
Surgery: Y/N
3DCRT66  (40–70) Surgery
9 4 Decrease in stimulated salivary flow to <25% of the pre-RT value
Opposing lateral fields and anterior field for 
the supraclavicular regions, electron beams 
used to boost the posterior neck region
PLATO 
RTS
Larynx, Hypopharynx, 
Oropharynx, Nasopharynx, 
Oral cavity, Nasal cavity, 
Unknown primary, Other
Hypopharynx, Oropharynx, 
Nasopharynx, Unknown 
primary
RTOG/EORTC
157 58
64 54-69 1,8-2,3
1996-2007
No
Yes
PLATO 
RTS 2,0
PLATO 
ITP, 1,1
yes (32%)
yes (24%)
8
ΔF ≤ 50% Reduction of the relative excretion rate (ΔF) of >50%
33
6 weeks after 
completing 
radiotherapy 
and then in 3-
month intervals 
within the first 
year
clinical examination; 
CT or MRI exam, post-
therapeutic salivary 
gland scintigraphy 
was performed 3 
months after RT
Oropharynx, nasopharynx, 
larynx, paranasal sinus, 
lymphoma
RT Lateral opposing fields, anterior and lateral wedged fields
yes (30%)
ΔF ≤ 75% Reduction of the relative excretion rate (ΔF) of >75%
ΔF ≤ 50% Reduction of the relative excretion rate (ΔF) of >50%
23 55,3
58,4
Lateral opposing fields, anterior and lateral 
wedged fields
6 MV, 
diferent 
electron 
energy
6 MV, 
diferent 
electron 
energy
1,8 - 2
1,8 - 2
ΔF ≤ 75% Reduction of the relative excretion rate (ΔF) of >75%
ΔF ≤ 50% Reduction of the relative excretion rate (ΔF) of >50%
19 54
RT (+Amifostine)
6, 15
KonRad/Vir
tuos 
(Siemens)
IMRT
ΔF ≤ 75% Reduction of the relative excretion rate (ΔF) of >75%
70 (52+18) 1,8 - 2,2
12 stimulated salivary flow to <25% of pre-RT value 347
stimulated salivary 
flow rates 
measurement using 
Lashley cups
1 year after RT
11
IMRT, 3DCRT
IMRT five equidistant beams ans seven beams
46-70 2
stimulated parotid 
saliva measurements 
using Lashley cups
3DCRT
Opposing lateral fields and anterior field for 
the supraclavicular regions, eletron beams to 
boost the posterior neck region
6
6
Larynx, Floor of mouth/oral 
cavity, Oropharynx, Nasal 
cavity, Hypopharynx, 
Nasopharynx, Other
Inversed planned IMRT or Opposed lateral 
beams
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Model Authors Publication Year
Organ delimitation Dosimetric parameters α/β (Gy) Sensitivity Method χ2 p D50 s γ m n k
Other 
parameters XX Axis
NTCP 
plot
 -  +  -  +  -  +  -  +  -  +  -  +
< 33
40-55
LKB Parotid glands V7, V15, V30 e V45, D mean
Maximum 
likelihood 28,4 25 34,7 0,18 0,1 0,33 1
Eisbruch 
et al,
Int, J,Radiat, 
Oncol, Biol, Phys, 
45  577–87
1999
Lyman 38 33 45 0,26 0,16 0,34 1,3 0,3 3,2
Seriality 37 32 46 #### 0 0,19 2 1 5,3
Critical Volume (Probit) 38 15 55 4,4 > 0,5
31 26 35 0,54 0,40 0,78 1
35 30 40 0,46 0,34 0,66 1
39 34 44 0,45 0,33 0,65 1
Lyman Parotid glands and submandibular D mean 3 Maximum likelihood 0.002 46.6 0.13 EUD
Scrimge
r et al,
Int, J, Radiation 
Oncology Biol, 
Phys,, Vol, 60, No, 
1,  pp,  178–185
2004
Mean dose-exponential;
EUD-exponential ;
Parallel-exponential;
Exponential-sigmoid; 
Exponential-sigmoid Comp-mean;
Exponential-sigmoid Comp-max
Blanco 
et al,
Int J Radiat Oncol 
Biol Phys 2005;62 2005
0,018 34 30 40 0,37 0,28 0,5 1
0,018 40 35 46 0,33 0,25 0,46 1
0,182 42 37 50 0,37 0,28 0,51 1
46 39 60 0,53 0,44 0,69 1
Parotid and submandibular glands 34,2 22 46,4 2,3 0,9 3,7
Parotid gland only 36,4 20,5 52,3 2,2 0,4 4
Parotid and submandibular glands 50,3 45,8 54,8 3,8 2,3 5,3
Parotid gland only 55,7 50,7 60,7 3,4 1,4 5,4
Parotid and submandibular glands 46,3 44 48,6 6,1 4,8 7,4
Parotid gland only 44,3 41,1 47,5 5,5 3,9 7,1
Parotid and submandibular glands 54,1 50 58,2 3,4 2,4 4,4
Parotid gland only 49,8 44,6 55 3,1 1,8 4,4
Parotid and submandibular glands 36,8 33,9 39,7 5 3,9 6,1
Parotid gland only 35 31,5 38,5 6,5 4,4 8,6
Parotid and submandibular glands 42,5 39,4 45,6 5,3 4 6,6
Parotid gland only 41 35,7 46,3 4,9 3,2 6,6
0,01 32 29 34 0,51 0,42 0,64 1
0,007 36 33 39 0,45 0,38 0,59 1
0,12 40 37 44 0,46 0,37 0,59 1
0,01 26 22 29 0,59 0,46 0,79 1
0,007 31 26 35 0,63 0,61 0,85 1
0,12 38 35 42 0,33 0,23 0,49 1
LKB 21,4 18,4 25,5 0,57 0,34 1,37 1
Seriality 20 16,7 24,1 0,01 0,77 0,31 1,42
LKB 27,8 23,6 33,7 0,49 0,27 1,42 1
Seriality 26,3 21,5 32,8 0,01 0,73 0,15 1,55
LKB 41,6 32,8 56,8 0,45 0,27 1,39 1
Seriality 40 32 54 0,01 0,8 0,35 1,62
40,5 36,8 44,1 0,36 0,28 0,44 1
39,7 37 43,3 0,44 0,35 0,54 1
Delta=
340,6 0,68 39,4 33,8 41,8 0,42 0,36 0,58 1,13 0,75 14,3
Delta=
339,2 <0,0001 39,9 37,3 42,8 0,4 0,34 0,51 1
n value was fixed 
at 1
LKB 39,4 33,8 41,8 0,42 0,36 0,58 1,13 0,75 14,3
mean dose 39,9 37,3 42,8 0,4 0,34 0,51 1
Seriality 38,8 36,5 43,5 0,08 0 0,65 0,95 0,7 1,3
Critical Volume (Probit) α=0,03;No=1; λ=0,65;NFSU=21
Parallel FSU 37 32 44 0,35 0,3 0,6 2,75 0,5 4,5 D50 = 30,5
VDth model (dose treshold) 0,48 0,35 0,65 Dth=30,5; rdV50=0,68
22,7 11,7 37,1 1,57 0,87 3,14
35 27,8 41,5 0,44 0,28 0,65
Submandibular 
gland dose-
response 
relationships after 
radiotherapy for 
h&n cancer
<0,05
D mean 
submand
ibular 
glands
Maxim
um 
Likelih
ood
Dmean
Volume 58, Issue 1, 
1 January 2004, 
Pages  175–184,  
Vol, 50, No, 1, pp, 
147–158,  2001
2001Maximum likelihood
Schilstr
a_2001 SchiltraParotid glands
Dmean 
parotidsparotid glands Dmean 3
α/β =4,5 Gy; 
similar 
results as 
α/β=3 Gy 
Kaneko 
et al,
Oral Oncol 
1998;34:140  –146, 1998
Marzi_
2009 Marzi
Int J Radiat Oncol 
Biol Phys, 2009 
Mar 15;73(4):1252-
9
2009
2007
Int, J, Radiation 
Oncology Biol, 
Phys,, Vol, 67, No, 
3,  pp,  651–659,  
2007
Int, J, Radiation 
Oncology Biol, 
Phys,, Vol, 72, No, 
4, pp, 1101–1109
2008
Houweli
ng et al,
LKB
maximum 
likelihood
Logistic Parotid glands D mean (sum of parotids) t student
D mean Roesink J, et al,
Int, J, Radiation 
Oncology Biol, 
Phys,, Vol, 51, No, 
4,  pp,  938–946
2001Lyman Maximum likelihood
References
Dose-volume histogram Fitting parameters
95% CI 95% CI 95% CI 95% CI 95% CI 95% CI
Model Parameters
NTCP Calculation
2010LKB Maximum LikelihoodDmeanparotid glands
Int J Radiat Oncol 
Biol Phys, 2010 
October 1; 78(2): 
449-453
Mean 
Dose
Dijkema
, et al,
2005n fixed at 1
Mean 
dose 
parotid 
gland
Braam et 
al,
Int, J, Radiat, 
Oncol, Biol, Phys, 
62  659–64
Lyman Parotid glands Mean dose
n fixed at 1
Mean 
dose; 
Dose
maximum 
likelihood
Dijkema
, et al,Lyman Parotid glands Mean dose
D (Gy) Munter_2006 MünterLog Logistic Mean dose
maximum 
likelihood
International 
Journal of 
Radiation 
Oncology Biology 
Physics; Volume 
76, Issue 4, 15 
March 2010, Pages 
1259–1265
2010
Mean 
dose; 
Mean 
BED
NR
left and right parotid glands were 
delineated on a contrast-enhanced 
computed tomography (CT)
between 
3 and 10
maximum 
likelihood
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Appendix B – MATLAB Codes 
 
x Function that imports the dose-volume information from the text files 
and saves in a matrix the information related to each file. 
 
function [dose, volume]=plot_DVH(filename,dvh)  
%--------------------------------------------------------------------------  
% done by Claudia Xavier in 7-10-2013 
%--------------------------------------------------------------------------  
%function [dose, volume]=plot_DVH(filename, dvh) 
%."dvh" includes: color, linestyle, linewidth, x_max,y_max, y_label 
%--------------------------------------------------------------------------  
A=load(filename); %read the file (2 columns) 
dose=A(:,1); %gives a name to column 1 
volume=A(:,2); %same for the 2nd 
clear A  
 
plot(dose,volume,'Color',dvh.color,'LineStyle',dvh.linestyle,'LineWidth',dvh.line
width) %for each patient 
hold on  
axis([0 dvh.x_max 0 dvh.y_max]) 
xlabel('Dose / Gy'), ylabel(dvh.y_label)  
title('Dose-Volume Histogram')  
 
 
x Function that runs the function plot_DVH and creates the mean dose-
volume curve of that group of dose-volume histograms. It saves the dose 
values, mean volume values and the total number of DVH used to 
calculate the mean curve. 
 
function 
[dose,mean_volume,k]=plot_DVH_allpatients(patientlist,filename,directory_resp
onse,dvh,dvh_mean) 
APPENDIXES 
 58 
%-------------------------------------------------------------------------- 
% done by Claudia Xavier in 7-10-2013 
%-------------------------------------------------------------------------- 
%[dose,mean_volume]=plot_DVH_allpatients(patientlist,filename,directory_resp
onse,dvh,dvh_mean) 
%."dvh" includes: color, linestyle, linewidth, x_max,y_max, y_label 
%-------------------------------------------------------------------------- 
dose = []; 
mean_volume = []; 
if strfind(filename, 'cum') 
    dvh.y_label='Volume/ %'; 
    dvh.y_max=100; 
elseif strfind(filename, 'dif') 
    dvh.y_label='Volume'; 
    dvh.y_max=10;  
end 
 
k=0; %counts 
matrix_volume=[]; 
for i=1:numel(patientlist) 
    dir_patient = int2str(patientlist(i)); %RID=patient directory 
    if exist([directory_response dir_patient], 'dir')  
        allfilename= [directory_response dir_patient '\' filename];  
        %if the patient directory exists it creates a new one with the hole information 
of  
% the files of the patient 
        if exist(allfilename, 'file') 
            [dose,volume]=plot_DVH(allfilename,dvh); 
            if ~isempty(volume) 
                k=k+1; %number of columns (different patients) 
                matrix_volume(:,k)=volume; %matrix of the volume only if the volume  
%exists for a certain file 
            end 
        end 
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    end 
end 
clear volume  
 
if ~isempty(matrix_volume) %in the case of existing a matrix volume 
    mean_volume=mean(matrix_volume,2); %mean volume is calculated for each  
%volume of all patients 
    plot(dose,mean_volume,'Color',dvh_mean.color, 
'LineStyle',dvh_mean.linestyle,... 
        'LineWidth',dvh_mean.linewidth) %plot the means 
end 
 
 
• Main function that reads the excel file with the data related to each 
patient in order to create the DVH. It creates several subplots in the same 
figure where each subplot runs the function plot_DVH_allpatients and the 
last subplot corresponds to the mean curves of the previous ones. 
 
function difer_patients_vector_parotid(filename,sheet,column,time) 
%-------------------------------------------------------------------------- 
% done by Claudia Xavier in 7-10-2013 
%-------------------------------------------------------------------------- 
%function difer_patients_vector(filename,sheet,column) 
% .to RUN this function -> insert it on the command window and 
change"filename" by the name of the file which 
% DVH you want to plot (don't forget the extention), “sheet" by the name of the 
excel sheet and "column" by the 
% letter(s) of the column of  interestt 
% .Analyze the complications that patients developed (numbers...UPDATED) 
%-------------------------------------------------------------------------- 
directory_response = 
'C:\Users\Administrator\Desktop\correrMatlab\PatientData\DVH\'; 
excel_directory    = 'C:\Users\Administrator\Desktop\correrMatlab\'; 
excel_directory    = [excel_directory 'Book15_population_without3D-CRT.xlsx']; 
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patients_nb        = 386; %number of patients in the excel sheet (in RID) 
last_line          = patients_nb +3;%+3 because excel file starts in line 4 
 
% FOR ALL PATIENTS: 
figure(1); 
dvh.color     = 'k'; 
dvh.linestyle = '-'; 
dvh.linewidth = 1; 
dvh.x_max     = 80;  
dvh_mean.y_label='Volume / %'; 
dvh_mean.linestyle= dvh.linestyle; 
dvh_mean.linewidth= dvh.linewidth+2; 
patientlist=xlsread(excel_directory, sheet, ['A4:A' int2str(last_line)]); %read 
numbers  
%in the excel sheet 
 
% DIVIDED: 
[column,~]=xlsread(excel_directory, sheet, [column int2str(4) ':' column 
int2str(last_line)]); % read strings in the 
% excel sheet 
[~,name]=fileparts(filename); %cut strings and return only part of it 
[~,name]=fileparts(name); 
 
variable=unique(column); %find ONCE the different variables in hole column 
index=find(~isnan(variable)); 
variable = variable(index); 
  
color='brcmgy'; %don't need to be a cell because it's only one letter 
linestyle={'-' '--' ':' '-.' '.' '*' '+' 'o' '>' 'x' '^' 'v' '<' 'p' 'h'}; %cell 
line_nb=2; 
column_nb=2; 
subplot_nb=line_nb*column_nb; %in this case its allways 6 (2x3) 
close all %close all windows (e.g.figures) before running the figures below 
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figure_nb=1; %so we can start at the 2nd one [mod(1/6)=1] 
k=1; %counts the number of plots 
k1=1; %counts the mean plots 
for i=1:numel(variable) 
    if mod(i,subplot_nb)==1 %i/6, if i is multiple of 6, the rest is 0 
          %but we want it to open a new figure in 7, 13,... so the ==1 
        figure_nb=figure_nb+1; %when rest==1 it creates a new figure 
        k=1; %when a new figure is created, k returns to 1 
    end 
    figure(figure_nb) %make the new figure 
    dvh_mean.color=color(k); %colors returns to the beginning when k=1 
    dvh_mean.linestyle=linestyle{figure_nb-1}; %linestyle returns to the 
beginning  
%when k=1 
    [dose,mean_volume,N_c]=subplot_DVH_allpatients(variable(i),column, 
patientlist,filename, ,... 
        directory_response, dvh, dvh_mean,line_nb, column_nb,k); 
    k=k+1; %counts the k values until 7(when k=[1-6] creates 6 plots in the figure 
and  
%when k=7 creates a new one) 
    if ~isempty(dose) %in the case of having dose values 
        figure(2) 
        subplot(line_nb,column_nb,4) 
        plot(dose,mean_volume,dvh_mean.color,'LineStyle',... 
            dvh_mean.linestyle,'LineWidth',2.5) %plots all the mean values in a single  
%plot 
        legend_variable{k1}=['G' int2str(variable(i))]; %creates a new cell only with 
the  
%tumours that were ploted 
        k1=k1+1; %number of mean plots 
        hold on 
        xlabel('Dose / Gy'), ylabel(dvh_mean.y_label) 
        title(['Mean DVHs of ' name ', ' time]) 
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    end 
end 
 
figure(2),legend(legend_variable) %calls this figure, in the end, to put the legend 
in it 
function 
[dose,mean_volume,N_c]=subplot_DVH_allpatients(variableX,column,patientlist
,filename,... 
    directory_response,dvh,dvh_mean,line_nb, column_nb,position) %creates the  
%subplots and saves the dose  
%and mean_volume data 
 
index=find(column==variableX); %finds a certain variable in the column and 
save  
%the correspondent RIDs 
if ~isempty(index) %in the case of having a list of RIDs for a tumortype(e.g.) 
    patientlist=patientlist(index); %patient list will corresponde to that 
    subplot(line_nb,column_nb,position) 
    [dose,mean_volume,N_c]=plot_DVH_allpatients(patientlist,filename,... 
    directory_response,dvh,dvh_mean); %N=length(index); %counts the number 
of  
%patients in each plot (to add nb. of patients)  
    title(['G' int2str(variableX) ', N_c=' int2str(N_c)]) 
    clear patientlist index 
else 
    dose=[]; 
    mean_volume = []; 
end 
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Appendix C – DRC and ROC curves 
Appendix C.1 – G0 vs. G2 
• IPSILATERAL PAROTID 
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• PAROTIDS SUM 
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• SALIVARY GLANDS – 4 structures 
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• SALIVARY GLANDS – 5 structures 
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Appendix C.2 – G0 vs. G1+G2 
• CONTRALATERAL PAROTID 
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• IPSILATERAL PAROTID 
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• PAROTIDS SUM 
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• SALIVARY GLANDS – 4 structures 
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• SALIVARY GLANDS - 5 structures 
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Appendix D – Seriality Model Parameters 
Appendix D.1 – G0 vs. G2 
 CONTRALATERAL PAROTID 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 135$ 74 54 112 85 68 
D50 (Gy) [68% CI] 9.6 [8.6-10.6] 22.6 [20.3-35.6] 32.2 [29.0-35.4] 38.6 [34.7-42.5] 51.7 [46.5-56.9] 48.3 [43.5-53.1] 
γ"[68%"CI] 0.150 [0.045-0.225] 0.224 [0.067-0.381] 0.609 [0.183-1.035] 0.707 [0.212-1.202] 0.444 [0.133-0.755] 0.685 [0.183-1.165] 
s" 0.008$ 0.056$ 1x10*4$ 1x10*4$ 1x10*4$ 1x10*4$
$
 IPSILATERAL PAROTID 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 133$ 74 52 110 85 67 
D50 (Gy) [68% CI] 17.4 [15.7-19.1] 27.9 [25.1-30.7] 33.4 [30.1-36.7] 43.7 [39.3-48.1] 56.5 [50.9-62.2] 61.9 [55.7-68.1] 
γ"[68%"CI] 0.518 [0.155-0.881] 0.383 [0.115-0.651] 0.593 [0.179-1.012] 0.594 [0.178-1.010] 0.442 [0.133-0.751] 0.489 [0.147-0.831] 
s" 1x10*4$ 0.005$ 1x10*4$ 1x10*4$ 1x10*4$ 1x10*4$
$
 PAROTIDS SUM 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 133$ 74 56 109 84 67 
D50 (Gy) [68% CI] 15.7 [14.1-17.3] 26.3 [23.7-28.9] 32.5 [29.3-35.8] 39.2 [35.3-43.1] 54.2 [48.8-59.6] 51.7 [46.5-56.9] 
γ"[68%"CI] 0.456 [0.137-0.775] 0.338 [0.101-0.575] 0.655 [0.197-1.114] 0.730 [0.219-1.241] 0.468 [0.140-0.796] 0.633 [0.190-1.076] 
s" 1x10*4$ 0.006$ 0.001$ 1x10*4$ 1x10*4$ 1x10*4$
$
 SALIVARY GLANDS_4 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 59$ 26 32 75 61 53 
D50 (Gy) [68% CI] 20.4 [18.4-22.4] 21.2 [19.1-23.3] 44.9 [40.4-49.4] 50.9 [45.8-56.0] 49.5 [44.6-54.5] 87.7 [78.9-96.5] 
γ"[68%"CI] 0.448 [0.134-0.762] 1x10*4$[3x10*5*2x10*4] 0.685 [0.206-1.165] 0.468 [0.140-0.796] 0.812 [0.244-1.380] 0.411 [0.123-0.699] 
s" 1x10*4$ 1x10*4$ 1x10*4$ 0.001$ 4x10*4$ 1x10*4$
$
 SALIVARY GLANDS_5 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 43$ 22 24 59 50 41 
D50 (Gy) [68% CI] 20.1 [18.1-22.1] 16.9 [15.2-18.6] 48.5 [43.7-53.4] 52.4 [47.2-57.6] 49.8 [44.8-54.8] 140.7 [126.6-154.8] 
γ"[68%"CI] 0.618 [0.185-1.051] 1x10*4$[3x10*5*2x10*4] 0.497 [0.149-0.845] 0.278 [0.083-0.473] 0.693 [0.208-1.178] 0.218 [0.065-0.371] 
s" 1x10*4$ 1x10*4$ 1x10*4$ 0.008$ 5x10*4$ 5x10*4$
$
 
 
Appendix D.2 – G0 vs. G1+G2 
 CONTRALATERAL PAROTID 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 291$ 171 97 188 145 98 
D50 (Gy) [68% CI] 3.9 [3.6-4.4] 7.1 [6.4-7.8] 20.6 [18.5-22.7] 23.1 [20.8-25.4] 24.8 [22.3-27.3] 33.6 [30.2-37.0] 
γ"[68%"CI] 1x10*4$[3x10*5*2x10*4] 1x10*4$[3x10*5*2x10*4] 0.429 [0.129-0.729] 0.247 [0.074-0.420] 0.225 [0.068-0.383] 0.547 [0.164-0.930] 
s" 0.039$ 0.139$ 0.026$ 3.3x10*4$ 1x10*4$ 0.026$
 
 IPSILATERAL PAROTID 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 289$ 171 95 185 145 97 
D50 (Gy) [68% CI] 4.5$[4.1*5.0] 8.6$[7.7*9.5] 23.1 [20.8-25.4] 25.4 [22.9-27.9] 26.4 [23.8-29.0] 37.1 [33.4-40.8] 
γ"[68%"CI] 1x10*4$[3x10*5*2x10*4] 0.017$[0.005*0.029] 0.435 [0.131-0.740] 0.225 [0.068-0.383] 0.200 [0.060-0.340] 0.416 [0.125-0.707] 
s" 1x10*4$ 0.010$ 0.002$ 1x10*4$ 1x10*4$ 0.021$
 
 PAROTIDS SUM 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 288$ 171 96 185 144 97 
D50 (Gy) [68% CI] 4.2$[3.8*4.6] 8.9$[8.0*9.8] 22.7 [20.4-25.0] 24.4 [22.0-26.8] 26.2 [23.6-28.8] 35.5 [32.0-39.1] 
γ"[68%"CI] 1x10*4$[3x10*5*2x10*4] 0.035$[0.011*0.060] 0.528 [0.158-0.898] 0.275 [0.083-0.468] 0.230 [0.069-0.391] 0.558 [0.167-0.949] 
s" 1x10*4$ 0.015$ 0.003$ 1x10*4$ 1x10*4$ 0.012$
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 SALIVARY GLANDS_4 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 123$ 71 62 116 104 75 
D50 (Gy) [68% CI] 5.7$[5.1*6.3] 7.9$[7.1*8.7] 28.5 [25.7-31.4] 30.0 [27.0-33.0] 30.8 [27.7-33.9] 39.9 [35.9-43.9] 
γ"[68%"CI] 1x10*4$[3x10*5*2x10*4] 1x10*4$[3x10*5*2x10*4] 0.567 [0.170-0.964] 0.284 [0.085-0.483] 0.333 [0.099-0.566] 0.573 [0.172-0.974] 
s" 1x10*4$ 1x10*4$ 1x10*4$ 0.004$ 0.008$ 1x10*4$
 
 SALIVARY GLANDS_5 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 100$ 57 49 97 88 63 
D50 (Gy) [68% CI] 4.8$[4.3*5.3] 7.5$[6.8*8.3] 25.8 [23.2-28.4] 23.7 [21.3-26.1] 24.5 [22.1-27.0] 36.3 [32.7-39.9] 
γ"[68%"CI] 1x10*4$[3x10*5*2x10*4] 1x10*4$[3x10*5*2x10*4] 0.341 [0.102-0.580] 0.126 [0.038-0.214] 0.109 [0.033-0.185] 0.283 [0.085-0.481] 
s" 1x10*4$ 1x10*4$ 1x10*4$ 0.016$ 0.029$ 1x10*4$
$
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Appendix E – Goodness of the fit 
Appendix E.1 – G0 vs. G2 
 CONTRALATERAL PAROTID 
Follow-up Time 7 wk 3 m 7 m 12 m 18 m 24 m 
PI Expected (%) 84.39$ 59.35 38.63 31.15 25.91 22.10 
PI Observed (%) 84.44 59.46 38.89 31.25 25.88 22.06 
Probability of Worst-fit 0.601$ 0.604$ 0.611$ 0.605$ 0.605$ 0.601$
Reduced X2 0.013$ 0.110$ 0.222$ 0.069$ 0.051$ 0.255$
Px(X2v,v) 1 0.954 0.637 0.999 0.995 0.858 
Area Under the Curve (AUC)" 0.620$ 0.657$ 0.685$ 0.699$ 0.714$ 0.706$
 
 IPSILATERAL PAROTID 
Follow-up Time 7 wk 3 m 7 m 12 m 18 m 24 m 
PI Expected (%) 83.87$ 57.70 44.03 30.89 25.87 22.38 
PI Observed (%) 84.21 58.11 44.23 30.91 25.88 22.39 
Probability of Worst-fit 0.601$ 0.613$ 0.610$ 0.603$ 0.601$ 0.601$
Reduced X2 0.023$ 0.167$ 0.522$ 0.188$ 0.166$ 0.204$
Px(X2v,v) 1 0.919 1 0.988 0.956 0.893 
Area Under the Curve (AUC)" 0.644$ 0.661$ 0.674$ 0.692$ 0.685$ 0.671$
 
 PAROTIDS SUM 
Follow-up Time 7 wk 3 m 7 m 12 m 18 m 24 m 
PI Expected (%) 84.03$ 57.80 40.77 32.08 25.01 22.43 
PI Observed (%) 84.21 58.11 41.07 32.11 25.00 22.39 
Probability of Worst-fit 0.601$ 0.610$ 0.617$ 0.605$ 0.602$ 0.601$
Reduced X2 0.029$ 0.119$ 0.437$ 0.142$ 0.086$ 0.250$
Px(X2v,v) 1 0.949 0.646 0.995 0.987 0.861 
Area Under the Curve (AUC)" 0.628$ 0.659$ 0.679$ 0.694$ 0.702$ 0.691$
 
 SALIVARY GLANDS_4 
Follow-up Time 7 wk 3 m 7 m 12 m 18 m 24 m 
PI Expected (%) 81.18$ 60.89 31.09 31.95 24.53 18.89 
PI Observed (%) 81.36 61.54 31.25 32.00 24.59 18.87 
Probability of Worst-fit 0.601$ 0.603$ 0.604$ 0.602$ 0.604$ 0.601$
Reduced X2 0.128$ 0.351$ 0.454$ 0.229$ 0.260$ 0.307$
Px(X2v,v) 0.879 0.553 0.635 0.876 0.771 0.579 
Area Under the Curve (AUC)" 0.651$ 0.668$ 0.674$ 0.672$ 0.685$ 0.657$
 
 SALIVARY GLANDS_5 
Follow-up Time 7 wk 3 m 7 m 12 m 18 m 24 m 
PI Expected (%) 85.86$ 66.54 33.25 37.25 27.93 24.36 
PI Observed (%) 86.05 68.18 33.33 37.29 28.00 24.39 
Probability of Worst-fit 0.601$ 0.605$ 0.602$ 0.601$ 0.603$ 0.601$
Reduced X2 0.040$ 0.332$ 1.990$ 0.322$ 0.356$ 0.303$
Px(X2v,v) 0.997 0.565 0.158 0.725 0.551 0.876 
Area Under the Curve (AUC)" 0.637$ 0.703$ 0.655$ 0.663$ 0.673$ 0.646$
 
 
 
Appendix E.2 – G0 vs. G1+G2 
 CONTRALATERAL PAROTID 
Follow-up Time 7 wk 3 m 7 m 12 m 18 m 24 m 
PI Expected (%) 92.11$ 80.46 65.78 58.42 56.56 45.95 
PI Observed (%) 92.78 80.70 65.98 58.51 56.55 45.92 
Probability of Worst-fit 0.603$ 0.601$ 0.604$ 0.604$ 0.602$ 0.602$
Reduced X2 0.011$ 0.033$ 0.027$ 0.033$ 0.093$ 0.061$
Px(X2v,v) 1 1 0.999 1 0.999 0.999 
Area Under the Curve (AUC)" 0.602$ 0.650$ 0.648$ 0.661$ 0.660$ 0.665$
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 IPSILATERAL PAROTID 
Follow-up Time 7 wk 3 m 7 m 12 m 18 m 24 m 
PI Expected (%) 92.54$ 80.48 65.00 57.76 56.53 46.47 
PI Observed (%) 92.73 80.70 65.26 57.84 56.55 46.49 
Probability of Worst-fit 0.601$ 0.601$ 0.604$ 0.603$ 0.601$ 0.601$
Reduced X2 0.089$ 0.039$ 0.095$ 0.070$ 0.048$ 0.160$
Px(X2v,v) 1 1 0.993 1 1 0.977 
Area Under the Curve (AUC)" 0.624$ 0.657$ 0.657$ 0.662$ 0.660$ 0.670$
 
 PAROTIDS SUM 
Follow-up Time 7 wk 3 m 7 m 12 m 18 m 24 m 
PI Expected (%) 92.62$ 80.48 65.34 58.81 56.26 45.45 
PI Observed (%) 92.71 80.70 65.63 58.92 56.25 45.36 
Probability of Worst-fit 0.601$ 0.601$ 0.604$ 0.604$ 0.601$ 0.601$
Reduced X2 0.011$ 0.046$ 0.081$ 0.170$ 0.002$ 0.160$
Px(X2v,v) 1 1 0.995 0.999 1 0.987 
Area Under the Curve (AUC)" 0.611$ 0.654$ 0.653$ 0.662$ 0.660$ 0.675$
 
 SALIVARY GLANDS_4 
Follow-up Time 7 wk 3 m 7 m 12 m 18 m 24 m 
PI Expected (%) 90.97$ 84.46 62.68 56.84 56.71 43.93 
PI Observed (%) 91.06 85.92 62.90 56.90 56.73 44.00 
Probability of Worst-fit 0.601$ 0.601$ 0.601$ 0.602$ 0.601$ 0.603$
Reduced X2 0.013$ 0.046$ 0.180$ 0.089$ 0.057$ 0.110$
Px(X2v,v) 1 0.987 0.837 0.999 0.999 0.954 
Area Under the Curve (AUC)" 0.631$ 0.726$ 0.655$ 0.661$ 0.660$ 0.670$
 
 SALIVARY GLANDS_5 
Follow-up Time 7 wk 3 m 7 m 12 m 18 m 24 m 
PI Expected (%) 93.96$ 85.75 62.68 61.82 60.22 50.76 
PI Observed (%) 95.00 87.72 62.90 61.86 60.23 50.79 
Probability of Worst-fit 0.601$ 0.601$ 0.602$ 0.601$ 0.601$ 0.602$
Reduced X2 0.004$ 0.078$ 0.178$ 0.043$ 0.110$ 0.078$
Px(X2v,v) 1 0.924 0.837 0.999 0.979 0.924 
Area Under the Curve (AUC)" 0.616$ 0.776$ 0.655$ 0.659$ 0.657$ 0.661$
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Appendix F – Dose values 
Appendix F.1 – G0 vs. G2 
 CONTRALATERAL PAROTID 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 135$ 74 54 112 85 68 
DBB Complications (Gy) 31.59±8.03 32.29±7.68 30.04±5.30 33.17±6.51 33.51±10.11 35.20±8.40 
DBB Complication-free (Gy) 22.95±11.64 26.58±13.16 24.65±10.35 27.11±9.81 27.60±9.51 28.92±9.32 
Threshold (Gy)" 24$ 30$ 28$ 28$ 33$ 27$
Odd Ratio [95% CI]" 8.8$[3.17–24.42]$ 4.00$[1.49–10.73]$ 3.85$[1.19–12.47]$ 5.27$[1.85–15.01]$ 3.25$[1.19–8.89]$ 3.94$[0.80–19.30]$
 
 IPSILATERAL PAROTID 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 133$ 74 52 110 85 67 
DBB Complications (Gy) 34.58±7.27 35.66±6.02 34.09±8.19 35.04±7.54 34.77±8.32 35.88±8.15 
DBB Complication-free (Gy) 27.39±12.16 30.04±14.38 28.18±10.15 30.15±9.07 31.05±8.75 32.60±7.93 
Threshold (Gy)" 30$ 27$ 30$ 28$ 29$ 47$
Odd Ratio [95% CI]" 5.38$[2.01–14.38]$ 23.10$[2.79–191.54]$ 4.01$[1.22–13.17]$ 4.38$[1.40–13.2]$ 3.40$[0.90–12.76]$ 12.75$[1.22–133.55]$
 
 PAROTIDS SUM 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 133$ 74 56 109 84 67 
DBB Complications (Gy) 33.36±7.20 34.10±6.24 31.14±4.76 34.14±6.80 34.18±9.08 35.54±7.97 
DBB Complication-free (Gy) 25.15±12.03 28.64±13.62 26.48±9.74 28.67±8.82 29.58±8.63 30.86±8.30 
Threshold (Gy)" 26$ 29$ 29$ 28$ 31$ 28$
Odd Ratio [95% CI]" 10.15$[3.59–28.72]$ 2.42$[1.00–7.39]$ 3.52$[1.14–10.88]$ 4.57$[1.60–13.10]$ 2.93$[1.01–8.53]$ 2.12$[0.53–8.49]$
 
 SALIVARY GLANDS_4 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 59$ 26 32 75 61 53 
DBB Complications (Gy) 38.14±6.15 * 36.36±3.96 36.63±4.62 37.84±3.46 36.69±4.51 
DBB Complication-free (Gy) 33.92±10.10 * 32.98±8.66 34.61±7.85 34.39±8.00 35.25±7.95 
Threshold (Gy)" 31$ *$ 33$ 33$ 36$ 35$
Odd Ratio [95% CI]" 13.2$[2.75–63.27]$ *$ 7.00$[1.18–41.36]$ 3.38$[1.09–10.44]$ 3.27$[0.91–11.81]$ 4.19$[0.80–22.06]$$
 
 SALIVARY GLANDS_5 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 43$ 22 24 59 50 41 
DBB Complications (Gy) 38.32±6.49 * 36.80±4.17 36.63±4.84 37.87±3.59 36.59±4.54 
DBB Complication-free (Gy) 31.99±11.50 * 34.57±8.53 35.37±8.04 35.16±7.87 36.11±7.77 
Threshold (Gy)" 32$ *$ 33$ 32$ 33$ 35$
Odd Ratio [95% CI]" 16.00$[2.19–117.09]$ *$ 9.00$[0.89–91.26]$$ 3.43$[0.85–13.80]$ 4.29$[0.83–22.03]$ 2.49$[0.54–11.44]$
 
 
 
Appendix F.2 – G0 vs. G1+G2 
 CONTRALATERAL PAROTID 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 291$ 171 97 188 145 98 
DBB Complications (Gy) * * 30.49±6.84 30.97±7.28 32.05±8.19 35.01±8.22 
DBB Complication-free (Gy) * * 24.76±10.36 27.12±9.76 28.01±9.17 29.09±9.31 
Threshold (Gy)" *$ *$ 27$ 25$ 25$ 26$
Odd Ratio [95% CI]" *$ *$ 3.93$[1.62–9.53]$ 2.99$[1.53–5.87]$ 3.35$[1.51–7.46]$ 4.47$[1.51–13.24]$
 
 IPSILATERAL PAROTID 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 289$ 171 95 185 145 97 
DBB Complications (Gy) * * 33.19±7.70 33.29±7.74 34.26±8.83 37.40±9.74 
DBB Complication-free (Gy) * * 28.16±9.95 30.23±9.03 30.61±9.41 32.84±7.87 
Threshold (Gy)" *$ *$ 25$ 25$ 25$ 44$
Odd Ratio [95% CI]" *$ *$ 5.79$[2.03–16.49]$ 4.01$[1.72–9.35]$ 2.41$[0.93–6.23]$ 11.29$[2.40–53.08]$
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 PAROTIDS SUM 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 288$ 171 96 185 144 97 
DBB Complications (Gy) * * 31.90±9.01 32.21±7.09 33.26±8.30 36.40±8.73 
DBB Complication-free (Gy) * * 26.49±9.73 28.93±9.00 29.70±8.60 30.94±8.20 
Threshold (Gy)" *$ *$ 25$ 26$ 27$ 39$
Odd Ratio [95% CI]" *$ *$ 5.73$[2.09–15.73]$ 3.30$[1.66–6.53]$ 2.97$[1.37–6.35]$ 4.14$[1.52–11.25]$
 
 SALIVARY GLANDS_4 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 123$ 71 62 116 104 75 
DBB Complications (Gy) * * 36.74±6.51 36.74±6.10 37.21±6.67 38.40±6.48 
DBB Complication-free (Gy) * * 32.81±8.50 34.61±7.93 34.54±7.66 35.03±7.83 
Threshold (Gy)" *$ *$ 31$ 33$ 31$ 31$
Odd Ratio [95% CI]" *$ *$ 5.04$[1.62–15.64]$ 2.66$[1.22–5.82]$ 4.51$[1.67–12.17]$ 4.03$[1.19–13.66]$
 
 SALIVARY GLANDS_5 
Follow-up Time 7 weeks 3 months 7 months 12 months 18 months 24 months 
Nb. Patients 100$ 57 49 97 88 63 
DBB Complications (Gy) * * 36.74±6.51 36.97±6.13 37.10±6.99 38.25±6.55 
DBB Complication-free (Gy) * * 32.81±8.50 35.38±8.03 35.38±7.38 36.25±7.84 
Threshold (Gy)" *$ *$ 31$ 30$ 31$ 35$
Odd Ratio [95% CI]" *$ *$ 5.04$[1.62–15.64]$ 2.80$[0.96–8.19]$ 3.43$[1.19–9.88]$ 2.35$[0.84–6.55]$
 
 
